

HLTH CORP
Form 10-Q
May 11, 2009

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the quarterly period ended March 31, 2009
- or
- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the transition period from _____ to _____

Commission file number: 0-24975

HLTH CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State of incorporation)

94-3236644

(I.R.S. employer identification no.)

**669 River Drive, Center 2
Elmwood Park, New Jersey**

(Address of principal executive office)

07407-1361

(Zip code)

(201) 703-3400

(Registrant's telephone number including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Edgar Filing: HLTH CORP - Form 10-Q

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

As of May 4, 2009, there were 103,591,004 shares of HLTH Common Stock outstanding (including unvested shares of restricted HLTH Common Stock issued under our equity compensation plans).

HLTH CORPORATION
QUARTERLY REPORT ON FORM 10-Q
For the period ended March 31, 2009

TABLE OF CONTENTS

	Page Number
<u>Forward-Looking Statements</u>	3
<u>PART I</u> <u>Financial Information</u>	
<u>Item 1.</u> <u>Financial Statements:</u>	
<u>Consolidated Balance Sheets as of March 31, 2009 and December 31, 2008</u> <u>(unaudited)</u>	4
<u>Unaudited Consolidated Statements of Operations for the three months ended</u> <u>March 31, 2009 and 2008</u>	5
<u>Unaudited Consolidated Statements of Cash Flows for the three months ended</u> <u>March 31, 2009 and 2008</u>	6
<u>Notes to Consolidated Financial Statements</u>	7
<u>Item 2.</u> <u>Management's Discussion and Analysis of Financial Condition and Results of</u> <u>Operations</u>	35
<u>Item 3.</u> <u>Quantitative and Qualitative Disclosures About Market Risk</u>	71
<u>Item 4.</u> <u>Controls and Procedures</u>	71
<u>PART II</u> <u>Other Information</u>	
<u>Item 1.</u> <u>Legal Proceedings</u>	72
<u>Item 2.</u> <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	72
<u>Item 6.</u> <u>Exhibits</u>	72
<u>Signatures</u>	73
<u>Exhibit Index</u>	E-1
<u>EX-10.1</u>	
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32.1</u>	
<u>EX-32.2</u>	

WebMD®, WebMD Health and Benefits Managersm, CME Circle®, eMedicine®, MedicineNet®, Medpulse®, Medscape®, Medsite®, POREX®, Publishers Circle®, RxList®, Select Quality Care®, Summex®, theheart.org® and The Little Blue Booktm are trademarks of HLTH Corporation or its subsidiaries.

Table of Contents

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains both historical and forward-looking statements. All statements, other than statements of historical fact, are or may be, forward-looking statements. For example, statements concerning projections, predictions, expectations, estimates or forecasts and statements that describe our objectives, future performance, plans or goals are, or may be, forward-looking statements. These forward-looking statements reflect management's current expectations concerning future results and events and can generally be identified by the use of expressions such as may, will, should, could, would, likely, predict, potential, continue, future, expect, anticipate, intend, plan, foresee, and other similar words or phrases, as well as statements in the future tense.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance and achievements expressed or implied by these statements. The following important risks and uncertainties could affect our future results, causing those results to differ materially from those expressed in our forward-looking statements:

- the failure to achieve sufficient levels of usage of www.webmd.com and our other public portals;
- failure to achieve sufficient levels of usage and market acceptance of new or updated products and services;
- difficulties in forming and maintaining relationships with customers and strategic partners;
- the inability to successfully deploy new or updated applications or services;
- the anticipated benefits from acquisitions not being fully realized or not being realized within the expected time frames;
- the inability to attract and retain qualified personnel;
- adverse economic conditions and disruptions in the capital markets;
- general business or regulatory conditions affecting the healthcare, information technology, Internet and plastics industries being less favorable than expected; and
- the other risks and uncertainties described in this Quarterly Report on Form 10-Q under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations - Factors That May Affect Our Future Financial Condition or Results of Operations."

These factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other factors, including unknown or unpredictable ones, could also have material adverse effects on our future results.

The forward-looking statements included in this Quarterly Report are made only as of the date of this Quarterly Report. Except as required by law or regulation, we do not undertake any obligation to update any forward-looking statements to reflect subsequent events or circumstances.

Table of Contents

**PART I
FINANCIAL INFORMATION**

ITEM 1. Financial Statements

HLTH CORPORATION

**CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data, unaudited)**

	March 31, 2009	December 31, 2008
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 552,483	\$ 629,848
Accounts receivable, net of allowance for doubtful accounts of \$1,694 at March 31, 2009 and \$1,301 at December 31, 2008	90,835	93,082
Prepaid expenses and other current assets	44,551	44,740
Assets of discontinued operations	129,253	131,350
Total current assets	817,122	899,020
Investments	275,885	288,049
Property and equipment, net	56,492	56,633
Goodwill	202,104	202,104
Intangible assets, net	30,570	32,328
Other assets	21,918	23,600
TOTAL ASSETS	\$ 1,404,091	\$ 1,501,734
LIABILITIES AND STOCKHOLDERS EQUITY		
Current liabilities:		
Accrued expenses	\$ 33,849	\$ 54,595
Deferred revenue	84,574	79,613
Due to broker for repurchases of convertible notes	8,484	
Liabilities of discontinued operations	98,506	100,771
Total current liabilities	225,413	234,979
1.75% convertible subordinated notes due 2023	273,483	350,000
31/8% convertible notes due 2025, net of discount of \$31,799 at March 31, 2009 and \$35,982 at December 31, 2008	250,201	264,018
Other long-term liabilities	19,899	21,816
Commitments and contingencies		
Stockholders' equity:		
HLTH stockholders' equity:		

Edgar Filing: HLTH CORP - Form 10-Q

Preferred stock, \$0.0001 par value; 5,000,000 shares authorized; no shares outstanding		
Common stock, \$0.0001 par value; 900,000,000 shares authorized; 458,376,157 shares issued at March 31, 2009; 458,284,729 shares issued at December 31, 2008	46	46
Additional paid-in capital	12,572,745	12,566,854
Treasury stock, at cost; 356,271,161 shares at March 31, 2009; 356,910,193 shares at December 31, 2008	(3,290,696)	(3,292,997)
Accumulated deficit	(8,776,203)	(8,776,618)
Accumulated other comprehensive loss	(11,888)	(587)
Total HLTH stockholders' equity	494,004	496,698
Noncontrolling interest in WHC	141,091	134,223
Total stockholders' equity	635,095	630,921
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 1,404,091	\$ 1,501,734

See accompanying notes.

Table of Contents**HLTH CORPORATION****CONSOLIDATED STATEMENTS OF OPERATIONS**

(In thousands, except per share data, unaudited)

	Three Months Ended March 31,	
	2009	2008
Revenue	\$ 90,264	\$ 80,650
Costs and expenses:		
Cost of operations	36,565	30,927
Sales and marketing	27,561	25,149
General and administrative	21,848	20,849
Depreciation and amortization	7,103	6,775
Interest income	2,262	11,936
Interest expense	6,536	6,525
Gain on repurchases of convertible notes	6,647	
Gain on sale of EBS Master LLC		538,024
Impairment of auction rate securities		60,108
Other expense, net	269	4,144
(Loss) income from continuing operations before income tax (benefit) provision	(709)	476,133
Income tax (benefit) provision	(1,217)	25,602
Equity in earnings of EBS Master LLC		4,007
Consolidated income from continuing operations	508	454,538
Consolidated income from discontinued operations (net of tax of \$1,277 in 2009 and \$2,722 in 2008)	517	3,057
Consolidated net income before noncontrolling interest	1,025	457,595
(Income) loss attributable to noncontrolling interest	(610)	3,845
Net income attributable to HLTH stockholders	\$ 415	\$ 461,440
Amounts attributable to HLTH stockholders:		
(Loss) income from continuing operations	\$ (194)	\$ 458,322
Income from discontinued operations	609	3,118
Net income attributable to HLTH stockholders	\$ 415	\$ 461,440
Basic (loss) income per common share:		
(Loss) income from continuing operations	\$ (0.00)	\$ 2.52
Income from discontinued operations	0.00	0.01
Net income attributable to HLTH stockholders	\$ 0.00	\$ 2.53

Edgar Filing: HLTH CORP - Form 10-Q

Diluted (loss) income per common share:		
(Loss) income from continuing operations	\$ (0.00)	\$ 2.03
Income from discontinued operations	0.00	0.01
Net income attributable to HLTH stockholders	\$ 0.00	\$ 2.04
Weighted-average shares outstanding used in computing (loss) income per common share:		
Basic	101,748	182,175
Diluted	101,748	228,159

See accompanying notes.

Table of Contents**HLTH CORPORATION****CONSOLIDATED STATEMENTS OF CASH FLOWS**

(In thousands, unaudited)

	Three Months Ended	
	March 31,	
	2009	2008
Cash flows from operating activities:		
Consolidated net income before noncontrolling interest	\$ 1,025	\$ 457,595
Adjustments to reconcile consolidated net income before noncontrolling interest to net cash (used in) provided by operating activities:		
Consolidated income from discontinued operations, net of tax	(517)	(3,057)
Depreciation and amortization	7,103	6,775
Equity in earnings of EBS Master LLC		(4,007)
Non-cash interest expense	2,799	2,661
Non-cash advertising	1,753	1,558
Non-cash stock-based compensation	9,154	5,940
Deferred income taxes	(2,604)	5,132
Gain on repurchases of convertible notes	(6,647)	
Gain on sale of EBS Master LLC		(538,024)
Impairment of auction rate securities		60,108
Changes in operating assets and liabilities:		
Accounts receivable	2,247	10,449
Prepaid expenses and other, net	(1,224)	17,493
Accrued expenses and other long-term liabilities	(20,741)	10,479
Deferred revenue	4,961	11,231
Net cash (used in) provided by continuing operations	(2,691)	44,333
Net cash provided by (used in) discontinued operations	2,001	(1,966)
Net cash (used in) provided by operating activities	(690)	42,367
Cash flows from investing activities:		
Proceeds from maturities and sales of available-for-sale securities	600	104,518
Purchases of available-for-sale securities		(177,150)
Purchases of property and equipment	(5,309)	(2,651)
Proceeds related to the sales of EBS Master LLC, EPS and ACS/ACP, net of fees	250	598,935
Other		1,195
Net cash (used in) provided by continuing operations	(4,459)	524,847
Net cash used in discontinued operations	(829)	(1,449)
Net cash (used in) provided by investing activities	(5,288)	523,398
Cash flows from financing activities:		
Proceeds from issuance of HLTH and WHC common stock	7,041	1,777
Repurchases of convertible notes	(78,183)	

Edgar Filing: HLTH CORP - Form 10-Q

Net cash (used in) provided by continuing operations	(71,142)	1,777
Net cash used in discontinued operations		(46)
Net cash (used in) provided by financing activities	(71,142)	1,731
Effect of exchange rates on cash	(245)	1,753
Net (decrease) increase in cash and cash equivalents	(77,365)	569,249
Cash and cash equivalents at beginning of period	629,848	536,879
Cash and cash equivalents at end of period	\$ 552,483	\$ 1,106,128

See accompanying notes.

Table of Contents

HLTH CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except share and per share data, unaudited)

1. Background and Basis of Presentation

Background

HLTH Corporation (HLTH or the Company) is a Delaware corporation that was incorporated in December 1995 and commenced operations in January 1996 as Healtheon Corporation. HLTH's Common Stock began trading on the Nasdaq National Market under the symbol HLTH on February 11, 1999 and now trades on the Nasdaq Global Select Market. The Company changed its name to Healtheon/WebMD Corporation in November 1999, to WebMD Corporation in September 2000, to Emdeon Corporation in October 2005 and to HLTH Corporation in May 2007.

WebMD Health Corp.'s (WHC) Class A Common Stock began trading on the Nasdaq National Market under the symbol WBMD on September 29, 2005 and now trades on the Nasdaq Global Select Market. As of March 31, 2009, the Company owned 48,100,000 shares of WHC Class B Common Stock, which represented 83.5% of the total outstanding Class A Common Stock and Class B Common Stock of WHC. WHC Class A Common Stock has one vote per share, while WHC Class B Common Stock has five votes per share. As a result, the WHC Class B Common Stock owned by the Company represented, as of March 31, 2009, 95.9% of the combined voting power of WHC's outstanding Common Stock. All shares of WHC Class B Common Stock outstanding on September 29, 2010 (the fifth anniversary of the closing date of WHC's initial public offering) will automatically be converted on a share-for-share basis for shares of WHC Class A Common Stock.

Basis of Presentation

The accompanying consolidated financial statements include the consolidated accounts of HLTH Corporation and its subsidiaries and have been prepared in United States dollars, and in accordance with U.S. generally accepted accounting principles (GAAP). The consolidated accounts include 100% of the assets and liabilities of the majority-owned WHC and the ownership interests of the noncontrolling stockholders of WHC are recorded as noncontrolling interest in WHC in the accompanying consolidated balance sheets.

In addition, the accompanying consolidated financial statements reflect the reclassification of the Company's Porex segment, ViPS segment and WebMD's Little Blue Book print directory business (LBB) as discontinued operations, as a result of the Company's intention to sell its Porex segment and LBB and due to the sale of its ViPS segment that was completed on July 22, 2008 (the ViPS Sale). See Note 2 for further details.

Effective January 1, 2009, the Company adopted Financial Accounting Standards Board's (FASB) Staff Position (FSP) Accounting Principles Board (APB) Opinion No. 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) (FSP APB 14-1) and Statement of Financial Accounting Standards (SFAS) No. 160, Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51 (SFAS 160). As required by FSP APB 14-1 and SFAS 160, the Company's historical consolidated financial statements have been retroactively adjusted to reflect the adoption of these standards. These accounting standards and the impact of their adoption on the historical financial statements are more fully described in Note 14, Adopted and Recently Issued Accounting Pronouncements.

Interim Financial Statements

Edgar Filing: HLTH CORP - Form 10-Q

The unaudited consolidated financial statements of the Company have been prepared by management and reflect all adjustments (consisting of only normal recurring adjustments) that, in the opinion of management, are necessary for a fair presentation of the interim periods presented. The results of operations for the three months ended March 31, 2009 are not necessarily indicative of the operating results to be expected for any

Table of Contents

HLTH CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

subsequent period or for the entire year ending December 31, 2009. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted under the Securities and Exchange Commission's (the SEC) rules and regulations.

The unaudited consolidated financial statements and notes included herein should be read in conjunction with the Company's audited consolidated financial statements and notes for the year ended December 31, 2008, which are included in the Company's Annual Report on Form 10-K filed with the SEC.

Accounting Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic, environmental and political factors, and changes in the Company's business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company's financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company's operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. Significant estimates and assumptions by management affect: the allowance for doubtful accounts, the carrying value of long-lived assets (including goodwill and intangible assets), the amortization period of long-lived assets (excluding goodwill and indefinite lived intangible assets), the carrying value, capitalization and amortization of software and Web site development costs, the carrying value of investments in auction rate securities, the provision for income taxes and related deferred tax accounts, certain accrued expenses, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.

Seasonality

The timing of the Company's revenue is affected by seasonal factors. Advertising and sponsorship revenue is seasonal, primarily as a result of the annual budget approval process of the advertising and sponsorship clients of the public portals. This portion of revenue is usually the lowest in the first quarter of each calendar year, and increases during each consecutive quarter throughout the year. Additionally, private portal licensing revenue is historically highest in the second half of the year as new customers are typically added during this period in conjunction with their annual open enrollment periods for employee benefits.

Net Income Attributable to HLTH Stockholders Per Common Share

Basic (loss) income per common share and diluted (loss) income per common share are presented in conformity with SFAS No. 128, Earnings Per Share (SFAS 128). In accordance with SFAS 128, basic (loss) income per common share has been computed using the weighted-average number of shares of common stock outstanding during the period.

Diluted (loss) income per common share has been computed using the weighted-average number of shares of common stock outstanding during the period, increased to give effect to potentially dilutive securities and assumes that any dilutive convertible notes were converted, only in the periods in which such effect is dilutive. Additionally, for purposes of calculating diluted (loss) income per common share of the Company, the numerator has been adjusted to consider the effect of potentially dilutive securities of WHC, which can dilute the portion of WHC's net income (loss) otherwise retained by the

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Company. The following table presents the calculation of basic and diluted (loss) income per common share (shares in thousands) for amounts attributable to HLTH stockholders:

	Three Months Ended March 31,	
	2009	2008
Amounts Attributable to HLTH Stockholders:		
Numerator:		
(Loss) income from continuing operations Basic	\$ (194)	\$ 458,322
Interest expense on convertible notes, net of tax		3,921
(Loss) income from continuing operations Diluted	\$ (194)	\$ 462,243
Income from discontinued operations, net of tax Basic and Diluted	\$ 609	\$ 3,118
Denominator:		
Weighted-average shares Basic	101,748	182,175
Employee stock options, restricted stock and warrants		3,968
Convertible notes		42,016
Adjusted weighted-average shares after assumed conversions Diluted	101,748	228,159
Basic (loss) income per common share:		
(Loss) income from continuing operations	\$ (0.00)	\$ 2.52
Income from discontinued operations	0.00	0.01
Net income attributable to HLTH stockholders	\$ 0.00	\$ 2.53
Diluted (loss) income per common share:		
(Loss) income from continuing operations	\$ (0.00)	\$ 2.03
Income from discontinued operations	0.00	0.01
Net income attributable to HLTH stockholders	\$ 0.00	\$ 2.04

The Company has excluded convertible subordinated notes and convertible notes, as well as certain outstanding warrants, restricted stock and stock options, from the calculation of diluted (loss) income per common share during the periods in which such securities were anti-dilutive. The following table presents the total number of shares that could potentially dilute (loss) income per common share in the future that were not included in the computation of diluted income per common share during the periods presented (shares in thousands):

	Three Months Ended	
	March 31,	
	2009	2008
Options, restricted stock and warrants	44,028	35,059
Convertible notes	35,887	
	79,915	35,059

Income Taxes

The income tax benefit of \$1,217 and provision of \$25,602 for the three months ended March 31, 2009 and 2008, respectively, represents taxes for federal, state and other jurisdictions. For the three months ended March 31, 2009, the gain on repurchases of convertible notes is provided for at a lower effective tax rate than

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

the Company's ordinary operations, resulting in an income tax benefit. For the three months ended March 31, 2008, while the majority of the gain on the 2008 EBSCo Sale (as defined in Note 4) was offset by net operating loss carryforwards, certain alternative minimum taxes and other state taxes were not offset, resulting in a provision of approximately \$24,000. Also, the income tax provision for the three months ended March 31, 2008 excludes a benefit for the impairment of auction rate securities, as it is currently not deductible for tax purposes.

Reclassifications

Certain reclassifications have been made to the prior period financial statements to conform to the current year presentation.

2. Discontinued Operations***WebMD's Little Blue Book Print Directory Business***

During March 2009, WebMD's Board of Directors decided to divest the Company's LBB as it is not strategic to the rest of WebMD's overall business, and initiated the process of seeking a buyer for LBB. Accordingly, the financial information for LBB has been reflected as discontinued operations in the accompanying consolidated financial statements. Summarized operating results for the discontinued operations of LBB are as follows:

	Three Months Ended March 31,	
	2009	2008
Revenue	\$ 572	\$ 1,032
Losses before taxes	715	700

The major classes of assets and liabilities of LBB are as follows:

	March 31, 2009	December 31, 2008
Assets of discontinued operations:		
Accounts receivable, net	\$ 395	\$ 1,058
Property and equipment, net	89	98
Goodwill	11,044	11,044
Intangible assets, net	298	362
Other assets	13	13
Total assets	\$ 11,839	\$ 12,575

Liabilities of discontinued operations:

Accrued expenses	\$	69	\$	113
Deferred revenue		1,577		876
Deferred tax liability		1,570		1,570
Total liabilities	\$	3,216	\$	2,559

ViPS and Porex

In November 2007, the Company announced its intention to explore potential sales transactions for its ViPS and Porex businesses and in February 2008, the Company announced its intention to divest these segments. On July 22, 2008, the ViPS business was sold and the divestiture process for Porex remains ongoing. Accordingly, the financial information for ViPS and Porex is reflected as discontinued operations in the accompanying consolidated financial statements.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)*****Porex***

Summarized operating results for the discontinued operations of Porex are as follows:

	Three Months Ended March 31,	
	2009	2008
Revenue	\$ 18,253	\$ 23,761
Earnings before taxes	2,400	3,476

The major classes of assets and liabilities of Porex are as follows:

	March 31, 2009	December 31, 2008
Assets of discontinued operations:		
Accounts receivable, net	\$ 11,297	\$ 13,866
Inventory	11,835	11,978
Property and equipment, net	22,025	21,487
Goodwill	42,095	42,297
Intangible assets, net	24,700	24,724
Deferred tax asset	1,420	1,420
Other assets	4,042	3,003
Total assets	\$ 117,414	\$ 118,775
Liabilities of discontinued operations:		
Accounts payable	\$ 2,326	\$ 1,601
Accrued expenses and other	6,850	6,654
Deferred tax liability	12,134	12,095
Total liabilities	\$ 21,310	\$ 20,350

ViPS

On July 22, 2008, the Company completed the ViPS Sale to an affiliate of General Dynamics Corporation. The Company received cash proceeds of \$223,175, net of a working capital adjustment, professional fees and other expenses associated with the ViPS Sale. In connection with the ViPS Sale, the Company recognized a pre-tax gain of \$96,969 and incurred approximately \$1,472 of professional fees and other expenses. Summarized operating results for the discontinued operations of ViPS are as follows:

	Three Months Ended March 31, 2008
Revenue	\$ 25,983
Earnings before taxes	2,851

EPS

On September 14, 2006, the Company completed the EPS Sale to Sage Software, Inc. (Sage Software), an indirect wholly owned subsidiary of The Sage Group plc. The Company has certain indemnity obligations to advance amounts for reasonable defense costs for initially ten, and now eight, former officers and directors of EPS, who were indicted in connection with the previously disclosed investigation by the United States Attorney for the District of South Carolina (the Investigation), which is more fully described in Note 10 Commitments and Contingencies. In connection with the EPS Sale, the Company agreed to indemnify Sage

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Software relating to these indemnity obligations. During the year ended December 31, 2007, based on information available at that time, the Company determined a reasonable estimate of the range of probable costs with respect to its indemnification obligation and accordingly, recorded an aggregate pre-tax charge of \$73,347, which represented the Company's estimate of the low end of the probable range of costs related to this matter. The Company had reserved the low end of the probable range of costs because no estimate within the range was a better estimate than any other amount. That estimate included assumptions as to the duration of the trial and pre-trial periods, and the defense costs to be incurred during these periods. During the three months ended June 30, 2008 and again during the three months ended December 31, 2008, the Company updated the estimated range of its indemnification obligation based on new information received during those periods, and as a result, recorded additional pre-tax charges of \$16,980 and \$12,098, respectively, each of which reflected increases in the low end of the probable range of costs related to this matter. The probable range of future costs with respect to this matter is estimated to be approximately \$36,400 to \$56,400 as of March 31, 2009, which includes costs that have been incurred prior to, but were not yet paid, as of March 31, 2009. The ultimate outcome of this matter is still uncertain, and the estimate of future costs includes assumptions as to the duration of the trial and the defense costs to be incurred during the remainder of the pre-trial period and during the trial period. Accordingly, the amount of cost the Company may ultimately incur could be substantially more than the reserve the Company has currently provided. If the recorded reserves are insufficient to cover the ultimate cost of this matter, the Company will need to record additional charges to its consolidated statement of operations in future periods. The accrual related to this obligation was \$36,391 and \$47,550 as of March 31, 2009 and December 31, 2008, respectively, and is included within liabilities of discontinued operations in the accompanying consolidated balance sheets.

As of March 31, 2009, also included within liabilities of discontinued operations related to this matter is \$37,589, which represents reimbursements received from the Company's insurance carriers between July 31, 2008 and March 31, 2009. The Company deferred recognizing these insurance reimbursements within the consolidated statement of operations given the pending Coverage Litigation, which is described below in Note 10. During January 2008, the Company also received reimbursement of expense costs related to defense costs from two insurance carriers in the amount of \$14,625 (see Note 10 for additional information). This amount was received through a settlement with these carriers, and accordingly, is not subject to the pending Coverage Litigation.

Also included in income from discontinued operations for the three months ended March 31, 2009 and 2008 is \$109 and \$152, respectively, related to the reversal of certain sales and use tax contingencies, which were indemnified by the Company for Sage Software, resulting from the expiration of statutes of limitations.

3. Repurchases of Convertible Notes

During the three months ended March 31, 2009, the Company repurchased \$76,517 principal amount of its 1.75% Convertible Subordinated Notes Due 2023 (1.75% Notes) for \$71,623 in cash, which includes \$4,712 that was paid after March 31, 2009 and is included in due to broker for repurchases of convertible notes in the accompanying consolidated balance sheets as of March 31, 2009. Also during the three months ended March 31, 2009, the Company repurchased \$18,000 principal amount of its 31/8% Convertible Notes Due 2025 (31/8% Notes) for \$15,044 in cash, which includes \$3,772 that was paid after March 31, 2009 and is included in due to broker for repurchases of convertible notes in the accompanying consolidated balance sheets as of March 31, 2009. The Company recognized an aggregate gain of \$6,647 related to the repurchases of the 1.75% Notes and 31/8% Notes during the three months ended March 31, 2009, which is reflected as gain on repurchases of convertible notes in the accompanying

consolidated statement of operations. The gain considers the write-off of remaining deferred issuance costs outstanding at the time these notes were repurchased.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****4. Emdeon Business Services**

On February 8, 2008, the Company entered into a Securities Purchase Agreement and simultaneously completed the sale of its 48% minority ownership interest in EBS Master LLC (EBSCo), which was reflected as an investment accounted for under the equity method, for \$574,617 in cash, net of professional fees and other expenses, to an affiliate of General Atlantic LLC and affiliates of Hellman & Friedman, LLC (the 2008 EBSCo Sale). In connection with the 2008 EBSCo Sale, the Company recognized a gain of \$538,024 during the three months ended March 31, 2008.

The Company s share of EBSCo s net earnings is reported as equity in earnings of EBS Master LLC in the accompanying consolidated statements of operations for the period January 1, 2008 through February 8, 2008, the closing date of the 2008 EBSCo Sale. The difference between the equity in earnings of EBS Master LLC in the accompanying consolidated statements of operations and 48% of the net income of EBSCo is principally due to the amortization of the excess of the fair value of EBSCo s net assets as adjusted for in purchase accounting, over the carryover basis of the Company s investment in EBSCo. The following is summarized financial information of EBSCo for the period January 1, 2008 through February 8, 2008:

	For the Period January 1, 2008 Through February 8, 2008
Revenue	\$ 94,481
Cost of operations	44,633
Net income	5,551

5. Segment Information

Segment information has been prepared in accordance with SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information (SFAS 131). The accounting policies of the segments are the same as the accounting policies for the consolidated Company. The performance of the Company s business is monitored based on earnings before interest, taxes, non-cash and other items. Other items include: a gain on the sale of our investment in EBS, an impairment charge related to investments in auction rate securities, legal expenses incurred by the Company, which reflect costs and expenses related to the investigation by the United States Attorney for the District of South Carolina and the SEC; the gain on the repurchases of the Company s convertible notes; income related to the reduction of certain sales and use tax contingencies; and professional fees, primarily consisting of legal, accounting and financial advisory services related to the merger between HLTH and WHC, which was terminated in October 2008.

The WebMD segment and Corporate segment are described as follows:

WebMD provides health information services to consumers, physicians and other healthcare professionals, employers and health plans through WebMD s public and private online portals and health-focused publications. WebMD s public portals for consumers enable them to obtain health and wellness information

(including information on specific diseases or conditions), check symptoms, locate physicians, store individual healthcare information, receive periodic e-newsletters on topics of individual interest and participate in online communities with peers and experts. WebMD's public portals for physicians and healthcare professionals make it easier for them to access clinical reference sources, stay abreast of the latest clinical information, learn about new treatment options, earn continuing medical education (CME) credit and communicate with peers. WebMD's public portals generate revenue primarily through the sale of advertising and sponsorship products, including CME services. The sponsors and advertisers include pharmaceutical, biotechnology, medical device and consumer products companies. WebMD's private portals enable employers and health plans to provide their employees and plan members with access to personalized health and benefit information and decision-support

Table of Contents

HLTH CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

technology that helps them make more informed benefit, provider and treatment choices. WebMD provides related services for use by such employees and members, including lifestyle education and personalized telephonic health coaching. WebMD generates revenue from its private portals through the licensing of these portals to employers and health plans either directly or through distributors. WebMD also provides e-detailing promotion and physician recruitment services for use by pharmaceutical, medical device and healthcare companies. WebMD also publishes *WebMD the Magazine*, a consumer magazine distributed to physician office waiting rooms.

Corporate includes personnel costs and other expenses related to executive personnel, legal, accounting, tax, internal audit, risk management, human resources and certain information technology functions, as well as other costs and expenses, such as professional fees including legal and audit services, insurance, costs of leased property and facilities, telecommunication costs and software maintenance expenses. Corporate expenses are net of \$1,035 and \$873 for the three months ended March 31, 2009 and 2008, respectively, which are costs allocated to WHC for services provided by the Corporate segment. In connection with the sale of a 52% interest in the Company's Emdeon Business Services segment during 2006 and the ViPS Sale, the Company entered into transition services agreements whereby the Company provided ViPS and EBSCo certain administrative services, including payroll, accounting, purchasing and procurement, tax, and human resource services, as well as information technology support. Additionally, EBSCo provided certain administrative services to the Company. These services were provided through the Corporate segment, and the related transition services fees that the Company charged to ViPS and EBSCo, net of the fee the Company paid to EBSCo, were also included in the Corporate segment, which were intended to approximate the cost of providing these services.

As a result of the Company's decision to divest LBB, the Company eliminated the separate segment presentation for WebMD Publishing and Other Services.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Summarized financial information for the WebMD segment and the Corporate segment and a reconciliation to consolidated income from continuing operations are presented below:

	Three Months Ended March 31,	
	2009	2008
Revenue		
WebMD:		
Advertising and sponsorship	\$ 65,428	\$ 56,482
Licensing	22,975	21,923
Print	1,861	2,245
	\$ 90,264	\$ 80,650
Earnings before interest, taxes, non-cash and other items		
WebMD	\$ 18,688	\$ 16,332
Corporate	(3,427)	(5,059)
	15,261	11,273
Interest, taxes, non-cash and other items		
Interest income	2,262	11,936
Interest expense	(6,536)	(6,525)
Income tax benefit (provision)	1,217	(25,602)
Depreciation and amortization	(7,103)	(6,775)
Non-cash stock-based compensation	(9,154)	(5,940)
Non-cash advertising	(1,753)	(1,558)
Gain on repurchases of convertible notes	6,647	
Equity in earnings of EBS Master LLC		4,007
Gain on sale of EBS Master LLC		538,024
Impairment of auction rate securities		(60,108)
Other expense, net	(333)	(4,194)
Consolidated income from continuing operations	508	454,538
Consolidated income from discontinued operations, net of tax	517	3,057
Consolidated net income before noncontrolling interest	1,025	457,595
(Income) loss attributable to noncontrolling interest	(610)	3,845
Net income attributable to HLTH Corporation	\$ 415	\$ 461,440

6. Stock-Based Compensation

The Company has various stock-based compensation plans (collectively, the Plans) under which directors, officers and other eligible employees receive awards of options to purchase HLTH Common Stock and restricted shares of HLTH Common Stock. Additionally, WHC has two similar stock-based compensation plans that provide for stock options and restricted stock awards based on WHC Class A Common Stock. The Company also maintained an Employee Stock Purchase Plan through April 30, 2008, which provided employees with the ability to buy shares of HLTH Common Stock at a discount. The following sections of this note summarize the activity for each of these plans.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****HLTH Plans**

The Company had an aggregate of 2,745,547 shares of HLTH Common Stock available for future grants under the Plans as of March 31, 2009. In addition to the Plans, the Company has granted options to certain directors, officers and key employees pursuant to individual stock option agreements. At March 31, 2009, there were options to purchase 4,104,881 shares of HLTH Common Stock outstanding to these individuals. The terms of these grants are similar to the terms of the options granted under the Plans and accordingly, the stock option activity of these individuals is included in all references to the Plans. Shares are issued from treasury stock when options are exercised or restricted stock is granted.

Stock Options

Generally, options under the Plans vest and become exercisable ratably over periods ranging from three to five years based on their individual grant dates subject to continued employment on the applicable vesting dates. The majority of options granted under the Plans expire within ten years from the date of grant. Options are granted at prices not less than the fair market value of HLTH Common Stock on the date of grant. The following table summarizes activity for the Plans:

	Shares	Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Life (In Years)	Aggregate Intrinsic Value (1)
Outstanding as of January 1, 2009	44,481,624	\$ 14.41		
Granted	137,500	10.39		
Exercised	(639,032)	8.58		
Cancelled	(1,063,123)	19.31		
Outstanding as of March 31, 2009	42,916,969	\$ 14.36	3.1	\$ 22,818
Vested and exercisable at the end of the period	37,814,764	\$ 14.96	2.3	\$ 18,182

(1) The aggregate intrinsic value is based on the market price of HLTH's Common Stock on March 31, 2009, which was \$10.35, less the applicable exercise price of the underlying option. This aggregate intrinsic value represents the amount that would have been realized if all of the option holders had exercised their options on March 31, 2009.

The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model, considering the assumptions noted in the following table.

	Three Months Ended March 31,	
	2009	2008
Expected dividend yield	0%	0%
Expected volatility	0.38	0.33
Risk-free interest rate	1.50%	2.82%
Expected term (years)	3.84	3.81
Weighted average fair value of options granted during the period	\$ 3.20	\$ 3.92

Expected volatility is based on implied volatility from traded options of HLTH Common Stock combined with historical volatility of HLTH Common Stock. Prior to January 1, 2006, only historical volatility was considered. The expected term represents the period of time that options are expected to be outstanding following their grant date, and was determined using historical exercise data. The risk-free rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)*****Restricted Stock Awards***

HLTH Restricted Stock consists of shares of HLTH Common Stock which have been awarded to employees with restrictions that cause them to be subject to substantial risk of forfeiture and restrict their sale or other transfer by the employee until they vest. Generally, HLTH Restricted Stock awards vest ratably over periods ranging from three to five years from their individual award dates subject to continued employment on the applicable vesting dates. The following table summarizes the activity of non-vested HLTH Restricted Stock:

	Shares	Weighted Average Grant Date Fair Value
Balance as of January 1, 2009	1,212,624	\$ 9.94
Granted	6,000	9.46
Vested	(115,207)	9.16
Balance as of March 31, 2009	1,103,417	\$ 10.02

Proceeds received from the exercise of options to purchase HLTH Common Stock were \$5,482 and \$1,588 for the three months ended March 31, 2009 and 2008, respectively. The intrinsic value related to the exercise of these stock options, as well as the fair value of shares of HLTH Restricted Stock that vested, was \$2,799 and \$2,375 for the three months ended March 31, 2009 and 2008, respectively.

WebMD Plans

During September 2005, WHC adopted the 2005 Long-Term Incentive Plan (as amended, the WHC Plan). Additionally, in connection with the acquisition of Subimo, LLC, in December 2006, WHC adopted the WebMD Health Corp. Long-Term Incentive Plan for Employees of Subimo, LLC (as amended, the Subimo Plan). The terms of the Subimo Plan are similar to the terms of the WHC Plan but it has not been approved by WHC stockholders. Awards under the Subimo Plan were made on the date of the Company's acquisition of Subimo, LLC in reliance on the NASDAQ Global Select Market exception to shareholder approval for equity grants to new hires. No additional grants will be made under the Subimo Plan. The WHC Plan and the Subimo Plan are referred to below as the WebMD Plans. The maximum number of shares of WHC Class A Common Stock that may be subject to options or restricted stock awards under the WebMD Plans was 14,980,574 as of March 31, 2009, subject to adjustment in accordance with the terms of the WebMD Plans. WHC had an aggregate of 2,068,457 shares of Class A Common Stock available for future grants under the WebMD Plans at March 31, 2009. Shares of WHC Class A Common Stock are issued from WHC's treasury stock when options are exercised or restricted stock is granted to the extent shares are available in WHC's treasury, otherwise new Class A Common Stock is issued in connection with these transactions.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)***Stock Options*

Generally, options under the WebMD Plans vest and become exercisable ratably over periods ranging from four to five years based on their individual grant dates subject to continued employment on the applicable vesting dates. The options granted under the WebMD Plans expire within ten years from the date of grant. Options are granted at prices not less than the fair market value of WHC's Class A Common Stock on the date of grant. The following table summarizes activity for the WebMD Plans:

	Shares	Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Life (In Years)	Aggregate Intrinsic Value (1)
Outstanding as of January 1, 2009	10,284,236	\$ 25.46		
Granted	226,000	22.53		
Exercised	(109,847)	17.50		
Cancelled	(278,275)	29.03		
Outstanding as of March 31, 2009	10,122,114	\$ 25.39	8.6	\$ 11,804
Vested and exercisable at the end of the period	2,374,252	\$ 24.35	6.9	\$ 7,711

(1) The aggregate intrinsic value is based on the market price of WHC's Class A Common Stock on March 31, 2009, which was \$22.30, less the applicable exercise price of the underlying option. This aggregate intrinsic value represents the amount that would have been realized if all of the option holders had exercised their options on March 31, 2009.

The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model, considering the assumptions noted in the following table.

	Three Months Ended March 31, 2009	2008
Expected dividend yield	0%	0%
Expected volatility	0.57	0.43
Risk-free interest rate	1.33%	2.31%

Edgar Filing: HLTH CORP - Form 10-Q

Expected term (years)	3.4	3.3
Weighted average fair value of options granted during the period	\$ 9.31	\$ 11.51

Expected volatility is based on implied volatility from traded options of WHC Class A Common Stock combined with historical volatility of WHC Class A Common Stock. The expected term represents the period of time that options are expected to be outstanding following their grant date, and was determined using historical exercise data of WHC employees who were previously granted HLTH stock options. The risk-free rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)*****Restricted Stock Awards***

WHC Restricted Stock consists of shares of WHC Class A Common Stock which have been awarded to employees with restrictions that cause them to be subject to substantial risk of forfeiture and restrict their sale or other transfer by the employee until they vest. Generally, WHC Restricted Stock awards vest ratably over periods ranging from four to five years from their individual award dates subject to continued employment on the applicable vesting dates. The following table summarizes the activity of non-vested WHC Restricted Stock:

	Shares	Weighted Average Grant Date Fair Value
Balance as of January 1, 2009	706,009	\$ 25.22
Granted	5,000	21.82
Vested	(11,463)	42.99
Forfeited	(21,283)	31.82
Balance as of March 31, 2009	678,263	\$ 24.69

Proceeds received from the exercise of options to purchase WHC Class A Common Stock were \$1,922 and \$589 for the three months ended March 31, 2009 and 2008, respectively. The intrinsic value related to the exercise of these stock options, as well as the fair value of shares of WHC Restricted Stock that vested, was \$790 and \$971 for the three months ended March 31, 2009 and 2008, respectively.

Employee Stock Purchase Plan

The Company's 1998 Employee Stock Purchase Plan, as amended from time to time (the "ESPP"), allowed eligible employees the opportunity to purchase shares of HLTH Common Stock through payroll deductions, up to 15% of a participant's annual compensation with a maximum of 5,000 shares available per participant during each purchase period. The purchase price of the stock was 85% of the fair market value on the last day of each purchase period. The ESPP provided for annual increases equal to the lesser of 1,500,000 shares, 0.5% of the outstanding common shares, or a lesser amount determined by the Board of Directors. The ESPP was terminated effective April 30, 2008 and there were no shares issued under the ESPP during the three months ended March 31, 2008.

Other

At the time of the WHC initial public offering and each year on the anniversary of the initial public offering, WHC issued shares of WHC Class A Common Stock to each non-employee director with a value equal to their annual board and committee retainers. The Company recorded \$85 of stock-based compensation expense during the three months ended March 31, 2009 and 2008 in connection with these issuances.

Additionally, the Company recorded stock-based compensation expense of \$279 during the three months ended March 31, 2008 in connection with a stock transferability right for shares that were issued in connection with the acquisition of Subimo, LLC by WHC.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Summary of Stock-Based Compensation Expense**

The following table summarizes the components and classification of stock-based compensation expense:

	Three Months Ended March 31,	
	2009	2008
HLTH Plans:		
Stock options	\$ 2,066	\$ 1,944
Restricted stock	1,902	1,373
WHC Plans:		
Stock options	4,550	2,406
Restricted stock	865	164
Employee Stock Purchase Plan		46
Other	88	350
 Total stock-based compensation expense	 \$ 9,471	 \$ 6,283
Included in:		
Cost of operations	\$ 1,623	\$ 1,116
Sales and marketing	1,550	1,126
General and administrative	5,981	3,698
 Consolidated income from continuing operations	 9,154	 5,940
Consolidated income from discontinued operations	317	343
 Total stock-based compensation expense	 \$ 9,471	 \$ 6,283

As of March 31, 2009, approximately \$18,168 and \$74,935 of unrecognized stock-based compensation expense related to unvested awards (net of estimated forfeitures) is expected to be recognized over a weighted-average period of approximately 2.2 years and 3.3 years, related to the HLTH Plans and the WebMD Plans, respectively.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****7. Stockholders Equity**

The following is a summary of the change in stockholders equity for the three months ended March 31, 2009 and 2008, including a summary of total comprehensive loss for the period:

	Three Months Ended March 31, 2009		
	HLTH Stockholders Equity	Noncontrolling Interest in WHC	Total Stockholders Equity
Balance as of the beginning of the period	\$ 496,698	\$ 134,223	\$ 630,921
Comprehensive loss:			
Net income	415	610	1,025
Net change in unrealized losses on securities	(10,583)	(981)	(11,564)
Foreign currency translation losses	(718)		(718)
Total comprehensive loss	(10,886)	(371)	(11,257)
Issuance of stock for option exercises and other issuances	5,214	1,827	7,041
Stock-based compensation expense	3,967	5,412	9,379
Repurchases of 31/8% convertible notes, net of tax	(989)		(989)
Balance as of the end of the period	\$ 494,004	\$ 141,091	\$ 635,095

	Three Months Ended March 31, 2008		
	HLTH Stockholders Equity	Noncontrolling Interest in WHC	Total Stockholders Equity
Balance as of the beginning of the period	\$ 642,808	\$ 131,353	\$ 774,161
Comprehensive income (loss):			
Net income (loss)	461,440	(3,845)	457,595
Unrealized losses on securities	(347)		(347)
Reversal of comprehensive loss related to EBS Master LLC	7,326		7,326
Foreign currency translation gains	3,354		3,354
Total comprehensive income (loss)	471,773	(3,845)	467,928
Issuance of stock for option exercises, ESPP and other issuances	1,308	469	1,777

Edgar Filing: HLTH CORP - Form 10-Q

Tax benefit realized from issuances of common stock and valuation reversal	1,440		1,440
Stock-based compensation expense	3,318	2,837	6,155
Gain on issuance of WHC Class A common stock and other	583	(583)	
Balance as of the end of the period	\$ 1,121,230	\$ 130,231	\$ 1,251,461

Accumulated other comprehensive loss includes:

	March 31, 2009	December 31, 2008
Foreign currency translation gains	\$ 7,373	\$ 8,091
Unrealized losses on securities, net	(19,261)	(8,678)
Total accumulated other comprehensive loss	\$ (11,888)	\$ (587)

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Deferred taxes are not included within accumulated other comprehensive loss because a valuation allowance was maintained for substantially all net deferred tax assets.

8. Fair Value of Financial Instruments and Non-Recourse Credit Facilities

SFAS No. 157, Fair Value Measurements (SFAS 157) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, SFAS 157 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

- Level 1:* Observable inputs such as quoted market prices in active markets for identical assets or liabilities, such as the Company's equity securities reflected in the table below.
- Level 2:* Observable market-based inputs or unobservable inputs that are corroborated by market data.
- Level 3:* Unobservable inputs for which there is little or no market data, which require the use of the reporting entity's own assumptions.

The Company did not have any Level 2 assets as of March 31, 2009 and December 31, 2008. The following table sets forth the Company's Level 1 and Level 3 financial assets that were measured at fair value on a recurring basis as of March 31, 2009 and December 31, 2008:

	March 31, 2009			December 31, 2008		
	Fair Value Estimates			Fair Value Estimates		
	Using			Using		
	Level 1	Level 3	Total	Level 1	Level 3	Total
Financial assets carried at fair value:						
Auction rate securities	\$	\$ 274,069	\$ 274,069	\$	\$ 286,552	\$ 286,552
Equity securities	1,816		1,816	1,497		1,497
Total financial assets carried at fair value	\$ 1,816	\$ 274,069	\$ 275,885	\$ 1,497	\$ 286,552	\$ 288,049

The following table reconciles the beginning and ending balances of the Company's Level 3 assets, which consist of the Company's auction rate securities for the three months ended March 31, 2009:

**March 31,
2009**

Edgar Filing: HLTH CORP - Form 10-Q

Fair value as of the beginning of the period	\$ 286,552
Redemptions	(600)
Unrealized loss included in other comprehensive loss	(11,883)
Fair value as of the end of the period	\$ 274,069

The Company holds investments in auction rate securities (ARS) which have been classified as Level 3 assets as described above. The types of ARS holdings the Company owns are backed by student loans, which are 97% guaranteed under the Federal Family Education Loan Program (FFELP), and all had credit ratings of AAA or Aaa when purchased. Historically, the fair value of the Company s ARS holdings approximated face value due to the frequent auction periods, generally every 7 to 28 days, which provided liquidity to these investments. However, since February 2008, all auctions involving these securities have failed. As a secondary market has yet to develop, these investments have been classified to long-term investments. The result of a failed auction is that these ARS holdings will continue to pay interest in accordance with their terms at each respective auction date; however, liquidity of the securities will be limited until there is a successful auction,

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

the issuer redeems the securities, the securities mature or until such time as other markets for these ARS holdings develop. During the three months ended March 31, 2008, the Company concluded that the estimated fair value of the ARS holdings no longer approximated the face value due to the lack of liquidity. The securities have been classified within Level 3 as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market due to the lack of trading in the securities.

The Company estimated the fair value of its ARS holdings using an income approach valuation technique. Using this approach, expected future cash flows were calculated over the expected life of each security and were discounted to a single present value using a market required rate of return. Some of the more significant assumptions made in the present value calculations were (i) the estimated weighted average lives for the loan portfolios underlying each individual ARS, which ranged from 4 to 14 years as of March 31, 2008 and (ii) the required rates of return used to discount the estimated future cash flows over the estimated life of each security, which considered both the credit quality for each individual ARS and the market liquidity for these investments. As of March 31, 2008, the Company concluded the fair value of its ARS holdings was \$302,842, of which \$141,044 relates to WHC, compared to a face value of \$362,950, of which \$168,450 relates to WHC. The impairment in value, or \$60,108, of which \$27,406 relates to WHC, was considered to be other-than-temporary and, accordingly, was recorded as an impairment charge within the consolidated statement of operations during the three months ended March 31, 2008.

In making the determination that the impairment was other-than-temporary, the Company considered (i) the current market liquidity for ARS, particularly student loan backed ARS, (ii) the long-term maturities of the loan portfolios underlying each ARS owned by the Company and (iii) the ability and intent of the Company to hold its ARS investments until sufficient liquidity returns to the auction rate market to enable the sale of these securities or until the investments mature.

During the three months ended March 31, 2009, the Company received \$600, all of which relates to WHC, associated with the partial redemption of certain of its ARS holdings, which represented 100% of their face value. As a result, as of March 31, 2009, the total face value of the Company's ARS holdings was \$354,400, of which \$164,200 related to WHC, compared to a fair value of \$274,069, of which \$127,033 related to WHC. During the three months ended March 31, 2009, the Company further reduced the carrying value of its ARS holdings by \$11,883, of which \$5,930 relates to WHC. The Company assessed this reduction to be temporary in nature, as this reduction in value resulted from fluctuations in interest rate and discount rate assumptions, and accordingly, this amount has been recorded as an unrealized loss in other comprehensive loss in the accompanying consolidated balance sheets. The Company may be required to record additional losses in future periods if the fair value of its ARS holdings deteriorates further.

Non-Recourse Credit Facilities

On May 6, 2008, the Company and WHC each entered into a non-recourse credit facility (the 2008 Credit Facilities) with affiliates of Citigroup, secured by their respective ARS holdings (including, in some circumstances, interest payable on the ARS holdings), that would allow the Company and WHC to borrow up to 75% of the face amount of the ARS holdings pledged as collateral under the respective 2008 Credit Facilities. No borrowings were made under the 2008 Credit Facilities.

On April 28, 2009, the Company entered into a new non-recourse credit facility and WebMD entered into an amended and restated facility, each with an affiliate of Citigroup (collectively, the 2009 Credit Facilities), replacing the 2008

Credit Facilities. As of the date of this Quarterly Report, no borrowings have been made under either of the 2009 Credit Facilities. The 2009 Credit Facilities are secured by the respective borrowers' ARS holdings (including, in some circumstances, interest payable on the ARS holdings). The Company and WHC can make borrowings under their respective 2009 Credit Facilities until April 27, 2010. Any borrowings outstanding under the 2009 Credit Facilities after February 26, 2010 become demand loans, subject to 60 days

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

notice, with recourse only to the pledged collateral. Loan proceeds may be used for general working capital purposes or other lawful business purposes of the borrower (including repurchases of its own securities), but not for purposes of buying, trading or carrying other securities. The interest rate applicable to borrowings under the 2009 Credit Facilities will be the Open Federal Funds Rate plus 3.95%. The maximum that can be borrowed under the respective 2009 Credit Facilities is 75% of the face amount of the pledged ARS holdings. As of the date of this Quarterly Report, the maximum the Company would be able to borrow is \$142,575 (based on its ARS holdings, excluding ARS held by WHC) and the maximum WHC would be able to borrow is \$123,075 (based on its ARS holdings). Removals of ARS from the pledged collateral (including upon their redemption or sale) will reduce the amount available for borrowing under the respective 2009 Credit Facilities.

The Company's 2009 Credit Facility is governed by a new loan agreement and WebMD's 2009 Credit Facility is governed by an amended and restated loan agreement, each of which contains customary representations and warranties of the borrower and certain affirmative covenants and negative covenants relating to the pledged collateral. Under each of the loan agreements, the borrower and the lender may, in certain circumstances, cause the pledged collateral to be sold, with the proceeds of any such sale required to be applied in full immediately to repayment of amounts borrowed.

9. Intangible Assets

Intangible assets subject to amortization consist of the following:

	March 31, 2009				December 31, 2008			
	Gross Carrying Amount	Accumulated Amortization	Net	Weighted Average Remaining Useful Life (a)	Gross Carrying Amount	Accumulated Amortization	Net	Weighted Average Remaining Useful Life (a)
	Amount	Amount	Amount		Amount	Amount	Amount	
Content	\$ 15,954	\$ (14,790)	\$ 1,164	1.5	\$ 15,954	\$ (14,541)	\$ 1,413	1.7
Customer relationships	34,057	(13,748)	20,309	8.6	34,057	(12,872)	21,185	8.8
Technology and patents	14,700	(13,870)	830	0.6	14,700	(13,370)	1,330	0.8
Trade names-definite lived	6,030	(2,227)	3,803	7.2	6,030	(2,094)	3,936	7.4
Trade names-indefinite lived	4,464		4,464	n/a	4,464		4,464	n/a
Total	\$ 75,205	\$ (44,635)	\$ 30,570		\$ 75,205	\$ (42,877)	\$ 32,328	

Amortization expense was \$1,758 and \$2,446 for the three months ended March 31, 2009 and 2008, respectively. Aggregate amortization expense for intangible assets is estimated to be:

Years Ending December 31:	
2009 (April 1st to December 31st)	\$ 4,550
2010	3,394
2011	2,628
2012	2,628
2013	2,628
Thereafter	10,278

10. Commitments and Contingencies

Litigation Regarding Distribution of Shares in Healtheon Initial Public Offering

Seven purported class action lawsuits were filed against Morgan Stanley & Co. Incorporated and Goldman Sachs & Co., underwriters of the initial public offering of the Company (then known as Healtheon Corporation) in the United States District Court for the Southern District of New York in the summer and fall of 2001. Three of these suits also named the Company and certain of its former officers and directors as

Table of Contents

HLTH CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

defendants. Similar suits were filed in connection with over 300 other initial public offerings that occurred in 1999, 2000 and 2001.

The complaints against the Company and its former officers and directors alleged violations of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 under that Act and Section 11 of the Securities Act of 1933 because of failure to disclose certain practices alleged to have occurred in connection with the distribution of shares in the Healthon initial public offering. Claims under Section 12(a)(2) of the Securities Act of 1933 were also brought against the underwriters. These claims were consolidated, along with claims relating to over 300 other initial public offerings, in the Southern District of New York.

After a lengthy mediation under the auspices of former United States District Judge Nicholas Politan, the issuer defendants in the consolidated action (including the Company), the issuers' insurance carriers, and the plaintiffs reached an agreement on a settlement to resolve the matter among the participating issuer defendants, their insurers, and the plaintiffs. The Company, and virtually all of the approximately 260 other issuer defendants who were eligible to participate, elected to participate in the settlement. Although the Company believed that the claims alleged in the lawsuits were primarily directed at the underwriters and, as they relate to the Company, were without merit, the Company believed that the settlement was beneficial to the Company because it would have reduced the time, expense and risks of further litigation, particularly since all the other eligible issuer defendants elected to participate, the Company's insurance carriers strongly supported the settlement, and the Company's insurance carriers, not the Company, would have paid any funds required under the settlement.

On June 10, 2004, plaintiffs submitted to the court a Stipulation and Agreement of Settlement with Defendant Issuers and Individuals. Although the district court had preliminarily approved the settlement, the parties terminated this settlement after the Second Circuit Court of Appeals reversed the district court's certification of the classes in six related focus cases in a ruling that was inconsistent with the proposed settlement class. After termination of this settlement, litigation proceeded in the six focus cases but was stayed in the cases involving the other issuers, including the Company.

After another lengthy mediation under the auspices of former Judges Politan and Daniel Weinstein, all the parties to the litigation reached a revised global settlement. This settlement calls for the underwriters and the insurers for the issuers to pay a total of \$586 million to settle all of the approximately 300 cases outstanding. The Company is not obligated to provide any money to fund the settlement. As with the previous proposed settlement, although the Company believes that the claims alleged in the lawsuits were primarily directed at the underwriters and, as they relate to the Company, are without merit, the Company believes that the settlement is beneficial to the Company because it will reduce the time, expense and risks of further litigation, particularly since all the other eligible issuer and underwriter defendants elected to participate, the Company's insurance carriers strongly support the settlement, and it requires no payment by the Company.

The settlement, which was submitted to the court on April 2, 2009, is subject to a number of contingencies, including but not limited to statutory notice requirements and certification of the settlement classes, and must be reviewed and approved by the court.

Porex Corporation v. Kleanthis Dean Haldopoulos, Benjamin T. Hirokawa and Micropore Plastics, Inc.

On September 24, 2005, the Company's subsidiary, Porex Corporation, filed a complaint in the Superior Court of Fulton County against two former employees of Porex, Dean Haldopoulos and Benjamin Hirokawa, and their corporation, Micropore Plastics, Inc. (Micropore), alleging misappropriation of Porex's trade secrets and breaches of Haldopoulos' and Hirokawa's employment agreements, and seeking monetary and injunctive relief. The lawsuit was subsequently transferred to the Superior Court of DeKalb County, Georgia. On October 24, 2005, the defendants filed an Answer and Counterclaims against Porex. In the Answer and Counterclaims, the defendants allege that Porex breached non-disclosure and standstill agreements in

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

connection with a proposed transaction between Porex and Micropore and engaged in fraud. The defendants also seek punitive damages and expenses of litigation. On February 13, 2006, the Superior Court granted a motion by the defendants for summary judgment with respect to Porex's trade secret claims, ruling that those claims are barred by the statute of limitations. Porex appealed that ruling to the Georgia Court of Appeals and, on March 27, 2007, the Georgia Court of Appeals reversed the ruling of the Superior Court. On April 16, 2007, the defendants filed a petition for certiorari with the Georgia Supreme Court, requesting that the Georgia Supreme Court review and reverse the March 27, 2007 decision of the Court of Appeals. On June 25, 2007, the Georgia Supreme Court denied the defendants' petition for certiorari. On or about July 31, 2007, the Georgia Court of Appeals formally returned the case to the Superior Court for further proceedings, and the parties thereafter proceeded with discovery. Discovery was suspended while the parties engaged in settlement discussions. The parties did not settle the matter, and discovery has now resumed. No trial date has been set. In view of the scheduling order currently governing the case, it is not expected that the case will be set for trial until, at the earliest, the first quarter of 2010. Porex plans to vigorously seek to enforce its rights in this litigation.

Investigations by United States Attorney for the District of South Carolina and the SEC

As previously disclosed, the United States Attorney for the District of South Carolina is conducting an investigation of the Company, which the Company first learned about on September 3, 2003. Based on the information available to the Company, it believes that the investigation relates principally to issues of financial accounting improprieties relating to Medical Manager Corporation, a predecessor of the Company (by its merger into the Company in September 2000), and, more specifically, its Medical Manager Health Systems, Inc. subsidiary. Medical Manager Health Systems was a predecessor to Emdeon Practice Services, Inc., a subsidiary that the Company sold to Sage Software in September 2006. The Company has been cooperating and intends to continue to cooperate fully with the U.S. Attorney's Office. As previously reported, the Board of Directors of the Company has formed a special committee consisting solely of independent directors to oversee this matter with the sole authority to direct the Company's response to the allegations that have been raised. As previously disclosed, the Company understands that the SEC is also conducting a formal investigation into this matter. In connection with the EPS Sale, the Company agreed to indemnify Sage Software with respect to this matter.

The United States Attorney for the District of South Carolina announced on January 10, 2005, that three former employees of Medical Manager Health Systems each had agreed to plead guilty to one count of mail fraud and that one such employee had agreed to plead guilty to one count of tax evasion for acts committed while they were employed by Medical Manager Health Systems. The three former employees include a Vice President of Medical Manager Health Systems responsible for acquisitions who was terminated for cause in January 2003; an executive who served in various accounting roles at Medical Manager Health Systems until his resignation in March 2002; and a former independent Medical Manager dealer who was a paid consultant to Medical Manager Health Systems until the termination of his services in 2002. According to the Informations, Plea Agreements and Factual Summaries filed by the United States Attorney in, and available from, the District Court of the United States for the District of South Carolina - Beaufort Division, on January 7, 2005, the three former employees and other then unnamed co-schemers were engaged in schemes between 1997 and 2002 that included causing companies acquired by Medical Manager Health Systems to pay the former vice president in charge of acquisitions and co-schemers kickbacks which were funded through increases in the purchase price paid by Medical Manager Health Systems to the acquired companies and that included fraudulent accounting practices to artificially inflate the quarterly revenues and earnings of Medical Manager Health Systems when it was an independent public company called Medical Manager Corporation from

1997 through 1999, when and after it was acquired by Syntec, Inc. in July 1999, and when and after it became a subsidiary of the Company in September 2000. A fourth former officer of Medical Manager Health Systems pled guilty to similar activities later in 2005.

Table of Contents

HLTH CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The fraudulent accounting practices cited by the government in the January 7, 2005 District Court filings included: causing companies acquired by Medical Manager Health Systems to reclassify previously recognized sales revenue as deferred income so that such deferred income could subsequently be reported as revenue by Medical Manager Health Systems and its parents in later periods; fabricating deferred revenue entries which could be used to inflate earnings when Medical Manager Health Systems acquired companies; causing companies acquired by Medical Manager Health Systems to inflate reserve accounts so that these reserves could be reversed in later reporting periods in order to artificially inflate earnings for Medical Manager Health Systems and its parents; accounting for numerous acquisitions through the pooling of interests method in order to fraudulently inflate Medical Manager Health Systems' quarterly earnings, when the individuals involved knew the transactions failed to qualify for such treatment; causing companies acquired by Medical Manager Health Systems to enter into sham purchases of software from Medical Manager Health Systems in connection with the acquisition which purchases were funded by increasing the purchase price paid by Medical Manager Health Systems to the acquired company and using these round trip sales to create fraudulent revenue for Medical Manager Health Systems and its parents; and causing Medical Manager Health Systems to book and record sales and training revenue before the revenue process was complete in accordance with GAAP and thereby fraudulently inflating Medical Manager Health Systems' reported revenues and earnings. According to the Informations to which the former employees have pled guilty, the fraudulent accounting practices resulted in the reported revenues of Medical Manager Health Systems and its parents being overstated materially between June 1997 and at least December 31, 2001, and reported quarterly earnings being overstated by at least one cent per share in every quarter during that period.

The documents filed by the United States Attorney in January 2005 stated that the former employees engaged in their fraudulent conduct in concert with senior management, and at the direction of senior Medical Manager officers. In its statement at that time, the United States Attorney for the District of South Carolina stated that the senior management and officers referred to in the Court documents were members of senior management of the Medical Manager subsidiary during the relevant time period.

On December 15, 2005, the United States Attorney announced indictments of the following former officers and employees of Medical Manager Health Systems: Ted W. Dorman, a former Regional Vice President of Medical Manager Health Systems, who was employed until March 2003; Charles L. Hutchinson, a former Controller of Medical Manager Health Systems, who was employed until June 2001; Maxie L. Juzang, a former Vice President of Medical Manager Health Systems, who was employed until August 2005; John H. Kang, a former President of Medical Manager Health Systems, who was employed until May 2001; Frederick B. Karl, Jr., a former General Counsel of Medical Manager Health Systems, who was employed until April 2000; Franklyn B. Krieger, a former Associate General Counsel of Medical Manager Health Systems, who was employed until February 2002; Lee A. Robbins, a former Vice President and Chief Financial Officer of Medical Manager Health Systems, who was employed until September 2000; John P. Sessions, a former President and Chief Operating Officer of Medical Manager Health Systems, who was employed until September 2003; Michael A. Singer, a former Chief Executive Officer of Medical Manager Health Systems and a former director of the Company, who was most recently employed by the Company as its Executive Vice President, Physician Software Strategies until February 2005; and David Ward, a former Vice President of Medical Manager Health Systems, who was employed until June 2005. The indictment charges the persons listed above with conspiracy to commit mail, wire and securities fraud, a violation of Title 18, United States Code, Section 371 and conspiracy to commit money laundering, a violation of Title 18, United States Code, Section 1956(h). The indictment charges Messrs. Sessions and Ward with substantive counts of money laundering, violations of Title 18, United States Code, Section 1957. The allegations set forth in the indictment

describe activities that are substantially similar to those described above with respect to the January 2005 plea agreements.

On February 27, 2007, the United States Attorney filed a Second Superseding Indictment with respect to the former officers and employees of Medical Manager Health Systems charged under the prior Indictment,

Table of Contents

HLTH CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

other than Mr. Juzang. The allegations set forth in the Second Superseding Indictment are substantially similar to those described above. Mr. Robbins passed away on September 27, 2008 and on October 15, 2008 the court granted a motion to dismiss Mr. Robbins from the Second Superseding Indictment.

On March 3, 2009 the trial court granted the motion of defendant Charles Hutchinson for a transfer of venue to Tampa, Florida. The effect of this order is that Mr. Hutchinson will not stand trial with the other seven defendants in Charleston, South Carolina but will be tried separately in Tampa, Florida. A date for such trial has not yet been scheduled. The trial of the other seven indicted former officers and directors of Medical Manager Health Systems had been scheduled for May 4, 2009 in Charleston. That trial date has been postponed however because, on March 27, 2009, the judge in the case removed himself from the case stating that in light of his advanced age it would not be fair to the parties for him to start what would likely be a lengthy trial. The trial date has not yet been rescheduled.

Based on the information it has obtained to date, including that contained in the court documents filed by the United States Attorney in South Carolina, the Company does not believe that any member of its senior management whose duties were not primarily related to the operations of Medical Manager Health Systems during the relevant time periods engaged in any of the violations or improprieties described in those court documents. The Company understands, however, that in light of the nature of the allegations involved, the U.S. Attorney's office has been investigating all levels of the Company's management. The Company has not uncovered information that it believes would require a restatement for any of the years covered by its financial statements. In addition, the Company believes that the amounts of the kickback payments referred to in the court documents have already been reflected in the financial statements of the Company to the extent required.

The Company has certain indemnity obligations to advance amounts for reasonable defense costs for the initial ten, and now eight, former officers and directors of EPS. During the years ended December 31, 2008 and 2007, the Company recorded a pre-tax charge of \$29,078 and \$73,347, respectively, related to its estimated liability with respect to these indemnity obligations. See Note 2 for a more detailed discussion regarding this charge.

Directors & Officers Liability Insurance Coverage Litigation

On July 23, 2007, the Company commenced litigation (the Coverage Litigation) in the Court of Chancery of the State of Delaware in and for New Castle County against ten insurance companies in which the Company is seeking to compel the defendant companies (collectively, the Defendants) to honor their obligations under certain directors and officers liability insurance policies (the Policies). The Company is seeking an order requiring the Defendants to advance and/or reimburse expenses that the Company has incurred and expects to continue to incur for the advancement of the reasonable defense costs of initially ten, and now eight, former officers and directors of the Company's former EPS subsidiary who were indicted in connection with the Investigation described above in this Note 10. The Company subsequently has settled with two of the insurance companies during January 2008, through which the Company received an aggregate amount of \$14,625. This amount was included within (loss) income from discontinued operations in the statement of operations during the three months ended December 31, 2007 and was included within prepaid expenses and other current assets in the accompanying consolidated balance sheet as of December 31, 2007.

Pursuant to a stipulation among the parties, the Coverage Litigation was transferred on September 13, 2007 to the Superior Court of the State of Delaware in and for New Castle County. The Policies were issued to the Company and

to EPS, a former subsidiary of the Company, which is a co-plaintiff with the Company in the Coverage Litigation (collectively, the Plaintiffs). EPS was sold in September 2006 to Sage Software and has changed its name to Sage Software Healthcare, Inc. (SSHI). In connection with the Company's sale of EPS to Sage Software, the Company retained certain obligations relating to the Investigation and agreed to indemnify Sage Software and SSHI with respect to certain expenses in connection with the Investigation. The Company retained the right to assert claims and recover proceeds under the Policies on behalf of SSHI.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Prior to the filing of the Second Amended Complaint which is discussed below, the Policies at issue in the Coverage Litigation consisted of two separate groups of insurance policies. Each group of policies consists of several layers of coverage, with different insurers having agreed to provide specified amounts of coverage at various levels. The first group of policies was issued to EPS in the amount of \$20,000 (the EPS Policies) and the second group of policies was issued to Syntec, Inc. (the former parent of EPS, which merged into the Company) in the amount of \$100,000, of which approximately \$3,600 was paid by the primary carrier with respect to another unrelated matter (the Syntec Policies). As of March 31, 2009, \$68,628 has been paid by insurance companies representing the EPS Policies and the Syntec Policies through a combination of payment under the terms of the Policies, payment under reservation of rights and settlement. Of this amount, \$37,589 has been reimbursed by the insurance companies subsequent to the Court's order on July 31, 2008 (described in more detail below). The Company has deferred recognizing this amount as income given the fact that the Coverage Litigation is ongoing and accordingly this amount has been deferred on the balance sheet as of March 31, 2009 within liabilities of discontinued operations. As a result of these payments, the Company has exhausted its coverage under the EPS Policies and has remaining coverage under the Syntec Policies of approximately \$39,000.

The carrier with the third level of coverage in the Syntec Policies filed a motion for summary judgment in the Coverage Litigation, which most of the carriers who have issued the Syntec Policies joined, which sought summary judgment that any liability to pay defense costs should be allocated among the three sets of policies available to the Company (including the policies with respect to which the Coverage Litigation relates and a third set of policies the issuers of which had not yet been named by the Company) such that the Syntec Policies would only be liable to pay about \$23,000 of the \$96,400 total coverage available under such policies. The Company filed its opposition to the motion together with its motion for summary judgment against such carrier and several other carriers who have issued the Syntec Policies seeking to require such carriers to advance payment of the defense costs that the Company is obligated to pay while the Coverage Litigation is pending. On July 31, 2008, the Superior Court for the State of Delaware denied the motion filed by the carriers seeking allocation and granted the Company's motion for partial summary judgment to enforce the duty of such carriers to advance and reimburse these costs.

Pursuant to the Court's order, the issuers of the Syntec Policies have been reimbursing the Company for its costs.

On September 9, 2008 and February 4, 2009, respectively, the eighth and ninth level carriers of the Syntec Policies notified the Company that they believe that they were not bound by the Court's July 31, 2008 order regarding the duty of the Syntec carriers to advance and reimburse defense costs. This resulted in the Company making a motion to the Court on February 23, 2009 to require such eighth and ninth level carriers to advance and reimburse defense costs. The Company has since settled with the eighth level carrier. Under the terms of the settlement such carrier will pay, in full and final settlement, an agreed-upon percentage of the policy amount against each payment of defense costs made by the Company if and when such policy becomes implicated. The Company's motion is pending against the ninth level carrier and, on April 15, 2009, such carrier made a cross-motion for summary judgment claiming that, in light of a policy endorsement applicable only to the ninth level carrier, because of the time period during which the conspiracy charged in the Second Superseding Indictment is alleged to have taken place, the Syntec Policy issued by such carrier does not cover the Company's indemnification obligations. The Company believes that such carrier's motion is without merit and is preparing its response, although there can be no assurance as to the outcome of the cross-motions.

On November 17, 2008, the Company filed a Second Amended Complaint which added four new insurance companies as defendants in the Coverage Action. These carriers are the issuers of a third set of policies (the Emdeon

Policies) that provide coverage with respect to the Company s indemnification obligations to the former officers and directors of the Company s former EPS subsidiary who were indicted in connection with the Investigation described above in this Note 10. The carriers who issued the Emdeon

Table of Contents

HLTH CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Policies have moved for summary judgment asserting that exclusions in the Emdeon Policies preclude coverage for the Company's indemnification obligations. The Company believes that these exclusions in the Emdeon Policies do not apply to the Company's claim and intends to oppose such motions, but there can be no assurance as to the outcome.

The insurance carriers assert that the Company's insurance policies provide that under certain circumstances, amounts advanced by the insurance companies in connection with the defense costs of the indicted individuals, may have to be repaid by the Company, although the \$14,625 that the Company has received in settlement from certain carriers is not subject to being repaid and any amounts paid by the eighth level carrier of the Synetic Policies will not have to be repaid. The Company has obtained an undertaking from each indicted individual pursuant to which, under certain circumstances, such individual has agreed to repay defense costs advanced on such individual's behalf.

There can be no assurance that the Company will ultimately prevail in the Coverage Litigation or that the Defendants will be required to provide funding on an interim basis pending the resolution of the Coverage Litigation. The Company intends to continue to satisfy its legal obligations to the indicted individuals with respect to advancement of amounts for their defense costs.

Other

In the normal course of business, the Company and its subsidiaries are involved in various other claims and legal proceedings. While the ultimate resolution of these matters has yet to be determined, the Company does not believe that their outcome will have a material adverse effect on the Company's consolidated financial position, results of operations or liquidity.

11. Restructuring

As a result of the completion of the integration of previously acquired businesses and efficiencies that the Company continues to realize from its infrastructure investments in WebMD, combined with the continued reduction in shared services performed within the Company's Corporate segment following the divestures of EPS, EBS and ViPS, the Company recorded a restructuring charge during the three months ended December 31, 2008 of \$7,416, of which \$2,910 relates to WebMD. This amount includes (i) \$3,575 related to the purchase of insurance for extended coverage during periods when the Company owned the divested businesses, (ii) \$3,391 related to severance and (iii) \$450 of costs to consolidate facilities and other exit costs. The remaining accrual related to this charge was \$1,876 and \$7,071 and is reflected in accrued expenses in the accompanying consolidated balance sheets as of March 31, 2009 and December 31, 2008, respectively. The decrease is the result of cash payments made during the three months ended March 31, 2009.

12. Related Party Transaction

Fidelity Human Resources Services Company LLC

In 2004, the Company's WebMD segment entered into an agreement with Fidelity Human Resources Services Company LLC (FHR) to integrate the WebMD's private portals product into the services FHR provides to its clients. FHR provides human resources administration and benefits administration services to employers. The Company recorded revenue of \$2,388 and \$2,438 during the three months ended March 31, 2009 and 2008,

respectively. Included in accounts receivable as of March 31, 2009 and December 31, 2008 was \$2,476 and \$2,070, respectively, related to the FHRS agreement.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****13. Other Expense, Net**

Other expense, net consists of the following items:

	Three Months Ended March 31,	
	2009	2008
Transition service fees (a)	\$ 64	\$ 50
Reduction of tax contingencies (b)	245	437
Legal expense (c)	(578)	(372)
Advisory expense (d)		(4,259)
Other expense, net	\$ (269)	\$ (4,144)

- (a) Represents the net fees received from ViPS and EBSCO in relation to their respective transition services agreements.
- (b) Represents the reduction of certain sales and use tax contingencies resulting from the expiration of various statutes of limitations.
- (c) Represents the costs and expenses incurred by the Company related to the investigation by the United States Attorney for the District of South Carolina and the SEC.
- (d) Represents professional fees, primarily consisting of legal, accounting and financial advisory services incurred by the Company related to the potential merger of HLTH into WHC, which was terminated in October 2008.

14. Adopted and Recently Issued Accounting Pronouncements***FSP APB 14-1***

Effective January 1, 2009, the Company adopted FSP APB 14-1. The adoption of FSP APB 14-1 affects the accounting for the Company's 3¹/₈% Convertible Notes due 2025 (3¹/₈% Notes). FSP APB 14-1 required cash settled convertible debt to be separated into debt and equity components at issuance and a value to be assigned to each. The value assigned to the debt component will be the estimated fair value, as of the issuance date, of a similar bond without the conversion feature. The difference between the bond's cash proceeds and this estimated fair value, which was \$61,300 at the time the 3¹/₈% Notes were issued during August 2005, represents a debt discount and will be amortized to interest expense over the period from issuance to August 2012 (when the 3¹/₈% Notes are first puttable at the option of the holder). The following table reflects the interest expense recognized and effective interest rate for the Company's 3¹/₈% Notes:

	Three Months Ended March 31,	
	2009	2008
Contractual coupon interest	\$ 2,321	\$ 2,344
Amortization of debt discount	2,139	2,004
Amortization of debt issuance costs	296	278
Interest expense	\$ 4,756	\$ 4,626
Effective interest rate	7.4%	7.4%

FSP APB 14-1 requires retrospective application for all periods presented in the Company's consolidated financial statements. The adoption of this accounting principle resulted in a decrease to the Company's net income attributable to HLTH stockholders of \$1,718 for the three months ended March 31, 2008 and an aggregate increase to stockholders' equity of \$37,966 as of December 31, 2008 however it did not have an impact on the Company's cash flows.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The effect of this change in accounting principle on the consolidated balance sheet as of December 31, 2008 and the consolidated statement of operation and cash flows for the three months ended March 31, 2008 are summarized as follows:

	Consolidated Balance Sheet	
	As	
	Previously Reported (a)	As Adjusted
As of December 31, 2008:		
Prepaid expenses and other current assets	\$ 41,169	\$ 44,740
Other assets	24,465	23,600
31/8% convertible notes due 2025	300,000	264,018
Additional paid-in capital	12,507,729	12,566,854
Accumulated deficit	(8,755,459)	(8,776,618)

	Consolidated Statement of Operations	
	As	
	Previously Reported (a)	As Adjusted
Three Months Ended March 31, 2008:		
Interest expense	\$ 4,607	\$ 6,525
Income tax provision	25,802	25,602
Consolidated income from continuing operations	456,256	454,538
Consolidated net income before noncontrolling interest	459,313	457,595
Net income attributable to HLTH stockholders	463,158	461,440
Basic income per common share:		
Income from continuing operations	\$ 2.52	\$ 2.52
Income from discontinued operations	0.02	0.01
Net income attributable to HLTH stockholders	\$ 2.54	\$ 2.53
Diluted income per common share:		
Income from continuing operations	\$ 2.03	\$ 2.03
Income from discontinued operations	0.01	0.01
Net income attributable to HLTH stockholders	\$ 2.04	\$ 2.04

**Consolidated Statement of
Cash Flows**

	As Previously Reported (a)	As Adjusted
Three Months Ended March 31, 2008:		
Consolidated net income before noncontrolling interest	\$ 459,313	\$ 457,595
Non-cash interest expense	743	2,661
Deferred income taxes	5,332	5,132

(a) The previously reported balances have been adjusted to reflect the reclassifications association with the presentation of LBB as a discontinued operation and the adoption of SFAS 160 (defined below).

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)*****SFAS 160***

On January 1, 2009, the Company adopted SFAS 160, which establishes accounting and reporting standards for noncontrolling interests, previously called minority interests. SFAS 160 requires that a noncontrolling interest be reported in the Company's consolidated balance sheets within equity and separate from the parent company's equity. Also, SFAS 160 requires consolidated net income to be reported at amounts inclusive of both the parent's and noncontrolling interest's shares and, separately, the amounts of consolidated net income attributable to the parent and noncontrolling interest, all on the face of the consolidated operating statement. In addition, discontinued operations and continuing operations reflected as part of the noncontrolling interest should be allocated between continuing operations and discontinued operations for the calculation of earnings per share. The presentation and disclosure requirements were applied retrospectively. Other than the change in presentation of noncontrolling interests, the adoption of SFAS 160 had no impact on the Consolidated Financial Statements.

SFAS 141R

Effective January 1, 2009, the Company adopted SFAS No. 141 (Revised 2007), *Business Combinations* (SFAS 141R), a replacement of SFAS No. 141. SFAS 141R provides that, upon initially obtaining control, an acquirer shall recognize 100 percent of the fair values of acquired assets, including goodwill, and assumed liabilities, with only limited exceptions, even if the acquirer has not acquired 100 percent of its target. As a consequence, the step acquisition model was eliminated. Additionally, SFAS 141R changes current practice, in part, as follows: (1) contingent consideration arrangements will be fair valued at the acquisition date and included on that basis in the purchase price consideration; (2) transaction costs will be expensed as incurred, rather than capitalized as part of the purchase price; (3) pre-acquisition contingencies, such as legal issues, will generally have to be accounted for in purchase accounting at fair value; and (4) in order to accrue for a restructuring plan in purchase accounting, the requirements in SFAS No. 146, *Accounting for Costs Associated with Exit or Disposal Activities*, would have to be met at the acquisition date. The adoption of SFAS 141R had no material impact on the Company's financial statements.

FSP FAS 107-1

In April 2009, the FASB issued Staff Position No. FAS 107-1 and APB 28-1, *Interim Disclosures about Fair Value of Financial Instruments* (FSP FAS 107-1). FSP FAS 107-1 amends SFAS No. 107, *Disclosures about Fair Value of Financial Instruments*, and requires disclosures about fair value of financial instruments in interim reporting periods. Such disclosures were previously required only in annual financial statements. FSP FAS 107-1 is effective for interim and annual reporting periods ending after June 15, 2009. The adoption of FSP FAS 107-1 is only expected to apply to financial statement disclosures.

FSP FAS 157-4

In April 2009, the FASB issued Staff Position No. FAS 157-4, *Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly* (FSP FAS 157-4). FSP 157-4 provides additional guidance for estimating fair value in accordance with FASB Statement No. 157, *Fair Value Measurement*, when the volume and level of activity for the asset or liability have

significantly decreased, as well as guidance on identifying circumstances that indicate a transaction is not orderly. FSP FAS 157-4 is effective for interim and annual reporting periods ending after June 15, 2009 and shall be applied prospectively. The Company is currently evaluating the requirements of this pronouncement and has not determined the impact, if any, that the adoption will have on the Company's consolidated financial statements.

Table of Contents

HLTH CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

FSP FAS 115-2

In April 2009, the FASB issued Staff Position No. FAS 115-2 and FAS 124-2, Recognition and Presentation of Other-Than-Temporary Impairments (FSP FAS 115-2). FSP FAS 115-2 provides additional guidance to make other-than-temporary impairments more operational and to improve the financial statement presentation of such impairments. FSP FAS 115-2 is effective for interim and annual reporting periods ending after June 15, 2009. The Company is currently evaluating the requirements of this pronouncement and has not determined the impact, if any, that the adoption will have on the Company's consolidated financial statements.

Table of Contents

ITEM 2. *Management's Discussion and Analysis of Financial Condition and Results of Operations*

*This Item 2 contains forward-looking statements with respect to possible events, outcomes or results that are, and are expected to continue to be, subject to risks, uncertainties and contingencies, including those identified in this Item. See *Forward-Looking Statements* on page 3.*

Overview

Management's discussion and analysis of financial condition and results of operations, or MD&A, is provided as a supplement to the Consolidated Financial Statements and notes thereto included elsewhere in this Quarterly Report and to provide an understanding of our results of operations, financial condition and changes in financial condition. Our MD&A is organized as follows:

Introduction. This section provides a general description of our company and operating segments, a description of the impact to our MD&A from the adoption of certain accounting pronouncements, background information on certain trends and developments affecting our company, and a discussion of how seasonal factors may impact the timing of our revenue.

Critical Accounting Estimates and Policies. This section discusses those accounting policies that are considered important to the evaluation and reporting of our financial condition and results of operations, and whose application requires us to exercise subjective or complex judgments in making estimates and assumptions. In addition, all of our significant accounting policies, including our critical accounting policies, are summarized in Note 2 to the Consolidated Financial Statements contained in our 2008 Annual Report on Form 10-K filed with the Securities and Exchange Commission (which we refer to as the SEC).

Results of Operations and Results of Operations by Operating Segment. These sections provide our analysis and outlook for the significant line items on our consolidated statements of operations, as well as other information that we deem meaningful to understand our results of operations on both a consolidated basis and an operating segment basis.

Liquidity and Capital Resources. This section provides an analysis of our liquidity and cash flows and discussions of our contractual obligations and commitments, as well as our outlook on our available liquidity of March 31, 2009.

Recent Accounting Pronouncements. This section provides a summary of the most recent authoritative accounting standards and guidance that have either been recently adopted by our company or may be adopted in the future.

Factors That May Affect Our Future Financial Condition or Results of Operations. This section describes circumstances or events that could have a negative effect on our financial condition or results of operations, or that could change, for the worse, existing trends in some or all of our businesses. The factors discussed in this section are in addition to factors that may be described elsewhere in this Quarterly Report.

In this MD&A, dollar amounts are in thousands, unless otherwise noted.

Introduction

Our Company

Edgar Filing: HLTH CORP - Form 10-Q

HLTH Corporation is a Delaware corporation that was incorporated in December 1995 and commenced operations in January 1996 as Healtheon Corporation. We changed our name to Healtheon/WebMD Corporation in November 1999, to WebMD Corporation in September 2000, to Emdeon Corporation in October 2005 and to HLTH Corporation in May 2007. Our Common Stock began trading on the Nasdaq National Market under the symbol HLTH on February 11, 1999 and now trades on the Nasdaq Global Select Market.

As of March 31, 2009, we owned 83.5% of the outstanding shares of capital stock of WebMD Health Corp. (which we refer to as WHC) through our ownership of WHC's Class B Common Stock. The remaining 16.5% of WHC's outstanding common stock are shares of WHC's Class A Common Stock, which trades on the Nasdaq

Table of Contents

Global Select Market under the symbol WBMD. Accordingly, as of March 31, 2009, our consolidated financial statements reflect the noncontrolling stockholders' share of equity and net income (loss) of WHC.

Adjustments to Reflect Certain Accounting Pronouncements

The information in this MD&A has been adjusted to reflect the adoption, effective January 1, 2009, of Financial Accounting Standards Board's Staff Position (which we refer to as FSP) Accounting Principles Board Opinion No. 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) (which we refer to as FSP APB 14-1) and Statement of Financial Accounting Standards No. 160, Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51 (which we refer to as SFAS 160). As required by FSP APB 14-1 and SFAS 160, our historical consolidated financial statements have been retroactively adjusted to reflect the adoption of these standards. These accounting standards and the impact of their adoption on the historical financial statements is more fully described in Note 14, Adopted and Recently Issued Accounting Pronouncements located in the Notes to Consolidated Financial Statements elsewhere in the Quarterly Report.

Segments

As a result of the planned sale of Porex and WebMD's Little Blue Book print directory business (describe below under Background Information on Certain Trends and Developments—Proposed Divestiture of WebMD's Little Blue Book Print Directory Business), which are classified as discontinued operations, our only remaining operating segment is our WebMD segment. The following is a description of the WebMD segment and our Corporate segment:

WebMD. WebMD is a leading provider of health information services to consumers, physicians and other healthcare professionals, employers and health plans through our public and private online portals and health-focused publications. WebMD's public portals for consumers enable them to obtain health and wellness information (including information on specific diseases or conditions), check symptoms, locate physicians, store individual healthcare information, receive periodic e-newsletters on topics of individual interest and participate in online communities with peers and experts. WebMD's public portals for physicians and healthcare professionals make it easier for them to access clinical reference sources, stay abreast of the latest clinical information, learn about new treatment options, earn continuing medical education (which we refer to as CME) credit and communicate with peers. WebMD public portals generate revenue primarily through the sale of advertising and sponsorship products, including CME services. WebMD sponsors and advertisers include pharmaceutical, biotechnology, medical device and consumer products companies. WebMD's private portals enable employers and health plans to provide their employees and members with access to personalized health and benefit information and decision-support technology that helps them to make more informed benefit, treatment and provider decisions. WebMD also provides related services for use by such employees and members, including lifestyle education and personalized telephonic health coaching. WebMD generates revenue from our private portals through the licensing of these portals to employers and health plans either directly or through distributors. WebMD also distributes our online content and services to other entities and generates revenue from these arrangements through the sale of advertising and sponsorship products and content syndication fees. WebMD also provides e-detailing promotion and physician recruitment services for use by pharmaceutical, medical device and healthcare companies. WebMD also publishes *WebMD the Magazine*, a consumer magazine distributed to physician office waiting rooms.

Corporate. Corporate includes personnel costs and other expenses related to executive personnel, legal, accounting, tax, internal audit, risk management, human resources and certain information technology functions, as well as other costs and expenses such as professional fees including legal and audit services, insurance, costs of leased property and facilities, telecommunication costs and software maintenance expenses.

Edgar Filing: HLTH CORP - Form 10-Q

Corporate expenses are net of \$1,035 and \$873 for the three months ended March 31, 2009 and 2008, respectively, which are costs allocated to WebMD for services provided by the Corporate segment. In connection with the sale of a 52% interest in our Emdeon Business Services segment (which we refer to as EBS) during 2006 and the sale of our ViPS segment, we entered into

Table of Contents

transition services agreements whereby we provided EBS and ViPS certain administrative services, including payroll, accounting, purchasing and procurement, tax, and human resource services, as well as information technology support. Additionally, EBS provided us certain administrative services. These services were provided through the Corporate segment, and the related transition services fees we charged to EBS and ViPS, net of the fee we paid to EBS, are also included in the Corporate segment, which were intended to approximate the cost of providing these services.

Background Information on Certain Trends and Developments

Trends Influencing the Use of Our Services. Several key trends in the healthcare and Internet industries are influencing the use of healthcare information services of the types we provide or are developing. Those trends are described briefly below:

Use of the Internet by Consumers and Physicians. The Internet has emerged as a major communications medium and has already fundamentally changed many sectors of the economy, including the marketing and sales of financial services, travel, and entertainment, among others. The Internet is also changing the healthcare industry and has transformed how consumers and physicians find and utilize healthcare information.

Healthcare consumers increasingly seek to educate themselves online about their healthcare related issues, motivated in part by the continued availability of new treatment options and in part by the larger share of healthcare costs they are being asked to bear due to changes in the benefit designs being offered by health plans and employers. The Internet has fundamentally changed the way consumers obtain health and wellness information, enabling them to have immediate access to searchable information and dynamic interactive content to check symptoms, assess risks, understand diseases, find providers and evaluate treatment options. The Internet is the consumers' fastest growing health information resource, according to a national study released in August 2008 by the Center for Studying Health System Change. Researchers found that 32 percent of American consumers (approximately 70 million adults) conducted online health searches in 2007, compared with 16 percent in 2001. More than half of those surveyed said the information changed their overall approach to maintaining their health. Four in five said the information helped them better understand how to treat an illness or condition.

The Internet has also become a primary source of information for physicians seeking to improve clinical practice and is growing relative to traditional information sources, such as conferences, meetings and offline journals.

Increased Online Marketing and Education Spending for Healthcare Products. Pharmaceutical, biotechnology and medical device companies spend large amounts each year marketing their products and educating consumers and physicians about them; however, only a small portion of this amount is currently spent on online services. We believe that these companies, which comprise the majority of the advertisers and sponsors of our public portals, are becoming increasingly aware of the effectiveness of the Internet relative to traditional media in providing health, clinical and product-related information to consumers and physicians, and this increasing awareness will result in increasing demand for our services. However, notwithstanding our general expectation for increased demand, our advertising and sponsorship revenue may vary significantly from quarter to quarter due to a number of factors, many of which are not in our control, and some of which may be difficult to forecast accurately, including general economic conditions and the following:

The majority of our advertising and sponsorship contracts are for terms of approximately four to twelve months. We have relatively few longer term advertising and sponsorship contracts.

The time between the date of initial contact with a potential advertiser or sponsor regarding a specific program and the execution of a contract with the advertiser or sponsor for that program may be subject to delays over which we have little or no control, including as a result of budgetary constraints of the advertiser or sponsor or their need for internal approvals.

Table of Contents

Other factors that may affect the timing of contracting for specific programs with advertisers and sponsors, or receipt of revenue under such contracts, include: the timing of FDA approval for new products or for new approved uses for existing products; the timing of FDA approval of generic products that compete with existing brand name products; the timing of withdrawals of products from the market; the timing of roll-outs of new or enhanced services on our public portals; seasonal factors relating to the prevalence of specific health conditions and other seasonal factors that may affect the timing of promotional campaigns for specific products; and the scheduling of conferences for physicians and other healthcare professionals.

Changes in Health Plan Design; Health Management Initiatives. In a healthcare market where the responsibility for healthcare costs and decision-making has been increasingly shifting to consumers, use of information technology (including personal health records) to assist consumers in making informed decisions about healthcare has also increased. We believe that through our WebMD Health and Benefits Manager tools, including our personal health record application, we are well positioned to play a role in this environment, and these services will be a significant driver for the growth of our private portals during the next several years. However, our growth strategy depends, in part, on increasing usage of our private portal services by our employer and health plan clients—employees and members, respectively. Increasing usage of our services requires us to continue to deliver and improve the underlying technology and develop new and updated applications, features and services. In addition, we face competition in the area of healthcare decision-support tools and online health management applications and health information services. Many of our competitors have greater financial, technical, product development, marketing and other resources than we do, and may be better known than we are. We also expect that, for clients and potential clients in the industries most seriously affected by recent adverse changes in general economic conditions (including those in the financial services and automotive industries), we may experience some reductions in initial contracts, contract expansions and contract renewals for our private portal services, as well as reductions in the size of existing contracts.

The healthcare industry in the United States and relationships among healthcare payers, providers and consumers are very complicated. In addition, the Internet and the market for online services are relatively new and still evolving. Accordingly, there can be no assurance that the trends identified above will continue or that the expected benefits to our businesses from our responses to those trends will be achieved. In addition, the market for healthcare information services is highly competitive and not only are our existing competitors seeking to benefit from these same trends, but the trends may also attract additional competitors.

Proposed Divestiture of the Little Blue Book Print Directory Business. In March 2009, WebMD's Board of Directors decided to divest WebMD's Little Blue Book Print Directory Business (which we refer to as LBB) as it is not strategic to WebMD's overall business. As a result of our intentions to divest and our expectation that this divestiture will be completed within one year, we reflected LBB as discontinued operations within the consolidated financial statements contained elsewhere in this Quarterly Report. The revenue and operating results of LBB had previously been reflected within our operating segment WebMD Publishing and Other Services. As a result of the decision to divest LBB, we eliminated the separate segment presentation for WebMD Publishing and Other Services. We are currently reporting revenue as (i) advertising and sponsorship, (ii) licensing and (iii) print, and are reporting WebMD as one operating segment.

Repurchases of Convertible Notes. During the three months ended March 31, 2009, we repurchased \$76,517 principal amount of our 1.75% Convertible Subordinated Notes Due 2023 (which we refer to as 1.75% Notes) for \$71,623 in cash, which includes \$4,712 that was paid after March 31, 2009. Also during the three months ended March 31, 2009, we purchased \$18,000 principal amount of our 31/8% Convertible Notes Due 2025 (which we refer to as 31/8% Notes) for \$15,044 in cash, which includes \$3,772 that was paid after March 31, 2009. We recognized an aggregate gain of \$6,647 related to the repurchases of the 1.75% Notes and 31/8% Notes during the three months

ended March 31, 2009. The gain considers the write-off of remaining deferred issuance costs outstanding at the time these notes were repurchased.

Non-Recourse Credit Facilities. On May 6, 2008, HLTH and WHC each entered into a non-recourse credit facility (the 2008 Credit Facilities) with affiliates of Citigroup, secured by their respective ARS holdings

Table of Contents

(including, in some circumstances, interest payable on the ARS holdings), that would allow HLTH and WHC to borrow up to 75% of the face amount of the ARS holdings pledged as collateral under the respective 2008 Credit Facilities. No borrowings were made under the 2008 Credit Facilities. A description of our ARS is included under Critical Accounting Estimates and Policies – Fair Value of Investments – below.

On April 28, 2009, HLTH entered into a new non-recourse credit facility and WHC entered into an amended and restated facility, each with an affiliate of Citigroup (collectively, we refer to as the 2009 Credit Facilities, replacing the 2008 Credit Facilities. As of the date of this Quarterly Report, no borrowings have been made under either of the 2009 Credit Facilities. The 2009 Credit Facilities are secured by the respective borrowers' ARS holdings (including, in some circumstances, interest payable on the ARS holdings). HLTH and WHC can make borrowings under their respective 2009 Credit Facilities until April 27, 2010. Any borrowings outstanding under the 2009 Credit Facilities after February 26, 2010 become demand loans, subject to 60 days notice, with recourse only to the pledged collateral. Loan proceeds may be used for general working capital purposes or other lawful business purposes of the borrower (including repurchases of its own securities), but not for purposes of buying, trading or carrying other securities. The interest rate applicable to borrowings under the 2009 Credit Facilities will be the Open Federal Funds Rate plus 3.95%. The maximum that can be borrowed under the respective 2009 Credit Facilities is 75% of the face amount of the pledged ARS holdings. As of the date of this Quarterly Report, the maximum that HLTH would be able to borrow is \$142,575 (based on its ARS holdings, excluding ARS held by WHC) and the maximum WHC would be able to borrow is \$123,075 (based on its ARS holdings). Removals of ARS from the pledged collateral (including upon their redemption or sale) will reduce the amount available for borrowing under the respective 2009 Credit Facilities. HLTH's 2009 Credit Facility is governed by a new loan agreement and WHC's 2009 Credit Facility is governed by an amended and restated loan agreement, each of which contains customary representations and warranties of the borrower and certain affirmative covenants and negative covenants relating to the pledged collateral. Under each of the loan agreements, the borrower and the lender may, in certain circumstances, cause the pledged collateral to be sold, with the proceeds of any such sale required to be applied in full immediately to repayment of amounts borrowed.

Directors & Officers Liability Insurance Coverage Litigation. On July 23, 2007, we commenced litigation (which we refer to as the Coverage Litigation) in the Court of Chancery of the State of Delaware in and for New Castle County against ten insurance companies in which we are seeking to compel the defendant companies (which we refer to as the Defendants) to honor their obligations under certain directors and officers liability insurance policies (which we refer to as the Policies). We are seeking an order requiring the Defendants to advance and/or reimburse expenses that we have incurred and expect to continue to incur for the advancement of the reasonable defense costs of initially ten, and now eight, former officers and directors of our former EPS subsidiary who were indicted in connection with the previously disclosed investigation by the United States Attorney for the District of South Carolina (which we refer to as the Investigation) described in Note 10, Commitments and Contingencies – located in Notes to Consolidated Financial Statements elsewhere in this Quarterly Report. We subsequently have settled with two of the insurance companies during January 2008, through which we received an aggregate amount of \$14,625.

Pursuant to a stipulation among the parties, the Coverage Litigation was transferred on September 13, 2007 to the Superior Court of the State of Delaware in and for New Castle County. The Policies were issued to our company and to EPS, our former subsidiary, which is our co-plaintiff in the Coverage Litigation (which we refer to collectively as the Plaintiffs). EPS was sold in September 2006 to Sage Software and has changed its name to Sage Software Healthcare, Inc. (which we refer to as SSHI). In connection with our sale of EPS to Sage Software, we retained certain obligations relating to the Investigation and agreed to indemnify Sage Software and SSHI with respect to certain expenses in connection with the Investigation. We retained the right to assert claims and recover proceeds under the Policies on behalf of SSHI.

Prior to the filing of the Second Amended Complaint which is discussed below, the Policies at issue in the Coverage Litigation consisted of two separate groups of insurance policies. Each group of policies consists of several layers of

coverage, with different insurers having agreed to provide specified amounts of coverage at various levels. The first group of policies was issued to EPS in the amount of \$20,000 (which we refer to as the EPS Policies) and the second group of policies was issued to Synetic, Inc. (the former parent of EPS,

Table of Contents

which merged into the HLTH) in the amount of \$100,000, of which approximately \$3,600 was paid by the primary carrier with respect to another unrelated matter (which we refer to as the Synthetic Policies). As of March 31, 2009, \$68,628 has been paid by insurance companies representing the EPS Policies and the Synthetic Policies through a combination of payment under the terms of the Policies, payment under reservation of rights and settlement. Of this amount, \$37,589 has been reimbursed by the insurance companies subsequent to the Court's order on July 31, 2008 (described in more detail below). As a result of these payments, we have exhausted our coverage under the EPS Policies and have remaining coverage under the Synthetic Policies of approximately \$39,000.

The carrier with the third level of coverage in the Synthetic Policies filed a motion for summary judgment in the Coverage Litigation, which most of the carriers who have issued the Synthetic Policies joined, which sought summary judgment that any liability to pay defense costs should be allocated among the three sets of policies available to our company (including the policies with respect to which the Coverage Litigation relates and a third set of policies the issuers of which had not yet been named by our company) such that the Synthetic Policies would only be liable to pay about \$23,000 of the \$96,400 total coverage available under such policies. We filed our opposition to the motion together with its motion for summary judgment against such carrier and several other carriers who have issued the Synthetic Policies seeking to require such carriers to advance payment of the defense costs that we are obligated to pay while the Coverage Litigation is pending. On July 31, 2008, the Superior Court for the State of Delaware denied the motion filed by the carriers seeking allocation and granted our motion for partial summary judgment to enforce the duty of such carriers to advance and reimburse these costs.

Pursuant to the Court's order, the issuers of the Synthetic Policies have been reimbursing our company for its costs.

On September 9, 2008 and February 4, 2009, respectively, the eighth and ninth level carriers of the Synthetic Policies notified our company that they believe that they were not bound by the Court's July 31, 2008 order regarding the duty of the Synthetic carriers to advance and reimburse defense costs. This resulted in our company making a motion to the Court on February 23, 2009 to require such eighth and ninth level carriers to advance and reimburse defense costs. We have since settled with the eighth level carrier. Under the terms of the settlement such carrier will pay, in full and final settlement, an agreed-upon percentage of the policy amount against each payment of defense costs we make if and when such policy becomes implicated. Our motion is pending against the ninth level carrier and, on April 15, 2009, such carrier made a cross-motion for summary judgment claiming that, in light of a policy endorsement applicable only to the ninth level carrier, because of the time period during which the conspiracy charged in the Second Superseding Indictment is alleged to have taken place, the Synthetic Policy issued by such carrier does not cover our indemnification obligations. We believe that such carrier's motion is without merit and are preparing our response, although there can be no assurance as to the outcome of the cross-motions.

On November 17, 2008, we filed a Second Amended Complaint which added four new insurance companies as defendants in the Coverage Action. These carriers are the issuers of a third set of policies (which we refer to as the Emdeon Policies) that provide coverage with respect to our indemnification obligations to the former officers and directors of our former EPS subsidiary who were indicted in connection with the Investigation described above in Note 10, Commitments and Contingencies located in Notes to the Consolidated Financial Statements elsewhere in this Quarterly Report. The carriers who issued the Emdeon Policies have moved for summary judgment asserting that exclusions in the Emdeon Policies preclude coverage for our indemnification obligations. We believe that these exclusions in the Emdeon Policies do not apply to our claim and intends to oppose such motions, but there can be no assurance as to the outcome.

The insurance carriers assert that our insurance policies provide that under certain circumstances, amounts advanced by the insurance companies in connection with the defense costs of the indicted individuals, we may have to repay, although the \$14,625 that we have received in settlement from certain carriers is not subject to being repaid and any amounts paid by the eighth level carrier of the Synthetic Policies will not have to be repaid. We have obtained an

undertaking from each indicted individual pursuant to which, under certain circumstances, such individual has agreed to repay defense costs advanced on such individual's behalf.

Table of Contents

There can be no assurance that we will ultimately prevail in the Coverage Litigation or that the Defendants will be required to provide funding on an interim basis pending the resolution of the Coverage Litigation. We intend to continue to satisfy our legal obligations to the indicted individuals with respect to advancement of amounts for their defense costs.

Indemnification Obligations to Former Officers and Directors of EPS. We have certain indemnity obligations to advance amounts for reasonable defense costs for initially ten, and now eight, former officers and directors of EPS, who were indicted in connection with the Investigation. In connection with the EPS Sale, we agreed to indemnify Sage Software relating to these indemnity obligations. During the year ended December 31, 2007, based on information available at that time, we determined a reasonable estimate of the range of probable costs with respect to its indemnification obligation and accordingly, recorded an aggregate pre-tax charge of \$73,347, which represented our estimate of the low end of the probable range of costs related to this matter. We have reserved the low end of the probable range of costs because no estimate within the range was a better estimate than any other amount. That estimate included assumptions as to the duration of the trial and pre-trial periods, and the defense costs to be incurred during these periods. During the three months ended June 30, 2008 and again during the three months ended December 31, 2008, we updated the estimated range of our indemnification obligation based on new information received during those periods, and as a result, recorded additional pre-tax charges of \$16,980 and \$12,098, respectively, each of which reflected increases in the low end of the probable range of costs related to this matter. The probable range of future costs with respect to this matter is estimated to be approximately \$36,400 to \$56,400 as of March 31, 2009 which includes costs that have been incurred prior to, but were not yet paid, as of March 31, 2009. The ultimate outcome of this matter is still uncertain, and the estimate of future costs includes assumptions as to the duration of the trial and the defense costs to be incurred during the remainder of the pre-trial period and during the trial period. Accordingly, the amount of cost we may ultimately incur could be substantially more than the reserve we have currently provided. If the recorded reserves are insufficient to cover the ultimate cost of this matter, we will need to record additional charges to our consolidated statement of operations in future periods. The accrual related to this obligation was \$36,391 and \$47,550 as of March 31, 2009 and December 31, 2008.

Seasonality

The timing of our revenue is affected by seasonal factors. Advertising and sponsorship revenue is seasonal, primarily due to the annual budget approval process of the advertising and sponsorship clients of our public portals. This portion of our revenue is usually the lowest in the first quarter of each calendar year, and increases during each consecutive quarter throughout the year. Additionally, our private portal licensing revenue is historically higher in the second half of the year as new customers are typically added during this period in conjunction with their annual open enrollment periods for employee benefits. The timing of revenue in relation to the expenses of the WebMD segment, much of which do not vary directly with revenue, has an impact on cost of operations, sales and marketing and general and administrative expenses as a percentage of revenue in each calendar quarter.

Critical Accounting Estimates and Policies

Our discussion and analysis of HLTH's financial condition and results of operations are based upon our Consolidated Financial Statements and Notes to Consolidated Financial Statements, which were prepared in conformity with U.S. generally accepted accounting principles. The preparation of financial statements requires us to make certain estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience, current business factors, and various other assumptions that we believe are necessary to consider in order to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and disclosure of contingent assets and liabilities. We are subject to uncertainties such as the impact of future events, economic, environmental and political factors, and changes in our business environment; therefore, actual results could differ from these estimates. Accordingly, the

accounting estimates used in preparation of our financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in

Table of Contents

reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to our consolidated financial statements.

We evaluate our estimates on an ongoing basis, including those related to revenue recognition, short-term and long-term investments, income taxes and tax contingencies, collectibility of customer receivables, long-lived assets including goodwill and other intangible assets, software and Web site development costs, certain accrued expenses, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.

We believe the following reflects our critical accounting policies and our more significant judgments and estimates used in the preparation of our consolidated financial statements:

Revenue Recognition Revenue from advertising is recognized as advertisements are delivered or as publications are distributed. Revenue from sponsorship arrangements, content syndication and distribution arrangements, and licenses of healthcare management tools and private portals as well as related health coaching services are recognized ratably over the term of the applicable agreement. Revenue from the sponsorship of CME is recognized over the period WebMD substantially completes its contractual deliverables as determined by the applicable agreements. When contractual arrangements contain multiple elements, revenue is allocated to each element based on its relative fair value determined using prices charged when elements are sold separately. In certain instances where fair value does not exist for all the elements, the amount of revenue allocated to the delivered elements equals the total consideration less the fair value of the undelivered elements. In instances where fair value does not exist for the undelivered elements, revenue is recognized when the last element is delivered.

Long-Lived Assets Our long-lived assets consist of property and equipment, goodwill and other intangible assets. Goodwill and other intangible assets arise from the acquisitions we have made. The amount assigned to intangible assets is subjective and based on our estimates of the future benefit of the intangible assets using accepted valuation techniques, such as discounted cash flow and replacement cost models. Our long-lived assets, excluding goodwill and indefinite lived intangible assets, are amortized over their estimated useful lives, which we determine based on the consideration of several factors including the period of time the asset is expected to remain in service. We evaluate the carrying value and remaining useful lives of long-lived assets, excluding goodwill and indefinite lived intangible assets, whenever indicators of impairment are present. We evaluate the carrying value of goodwill and indefinite lived intangible assets annually, or whenever indicators of impairment are present. We use a discounted cash flow approach to determine the fair value of goodwill and indefinite lived intangible assets. Long-lived assets held for sale are reported at the lower of cost or fair value less cost to sell. There was no impairment of goodwill or indefinite lived intangible assets noted as a result of our impairment testing in 2008.

Fair Value of Investments We hold investments in ARS which are backed by student loans, which are 97% guaranteed under the Federal Family Education Loan Program (FFELP), and which had credit ratings of AAA or Aaa when purchased. Historically, the fair value of our ARS investments approximated face value due to the frequent auction periods, generally every 7 to 28 days, which provided liquidity to these investments. However, since February 2008, all auctions involving these securities have failed. As a secondary market has yet to develop, these investments have been reclassified to long-term investments. The result of a failed auction is that these ARS will continue to pay interest in accordance with their terms at each respective auction date; however, liquidity of the securities will be limited until there is a successful auction, the issuer redeems the securities, the securities mature or until such time as other markets for these ARS develop. We cannot be certain regarding the amount of time it will take for an auction market or other markets to develop.

Accordingly, during the three months ended March 31, 2008, we concluded that the estimated fair value of the

ARS no longer approximated the face value due to the lack of liquidity and accordingly, we recorded an other-than-temporary impairment as of March 31, 2008.

Table of Contents

As of and subsequent to March 31, 2008, we estimated the fair value of our ARS holdings using an income approach valuation technique. Using this approach, expected future cash flows are calculated over the expected life of each security and are discounted to a single present value using a market required rate of return. Some of the more significant assumptions made in the present value calculations include (i) the estimated weighted average lives for the loan portfolios underlying each individual ARS and (ii) the required rates of return used to discount the estimated future cash flows over the estimated life of each security, which considered both the credit quality for each individual ARS and the market liquidity for these investments.

Our ARS have been classified as Level 3 assets in accordance with Statement of Financial Accounting Standards (which we refer to as SFAS) No. 157, Fair Value Measurements, as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market due to the lack of trading in the securities. If different assumptions were used for the various inputs to the valuation approach including, but not limited to, assumptions involving the estimated lives of the ARS investments, the estimated cash flows over those estimated lives, and the estimated discount rates applied to those cash flows, the estimated fair value of these investments could be significantly higher or lower than the fair value we determined. We continue to monitor the market for ARS as well as the individual ARS investments we own. We may be required to record additional losses in future periods if the fair value of our ARS deteriorates further.

Sale of Subsidiary Stock Our WHC subsidiary issues its Class A Common Stock in various transactions, which results in a dilution of our percentage ownership in WHC. We account for the sale of WHC Class A Common Stock in accordance with the SEC's Staff Accounting Bulletin No. 51 Accounting for Sales of Stock by a Subsidiary, as amended by SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements an amendment of ARB No. 51 (which we refer to as SFAS 160). The difference between the carrying amount of our investment in WHC before and after the issuance of WHC Class A Common Stock is considered either a gain or loss and is reflected as a component of our stockholders' equity. During the three months ended March 31, 2009 and 2008, WHC stock options exercised and restricted stock awards were released in accordance with WHC's equity plans. The issuance of these shares resulted in an aggregate gain of \$757 during the three months ended March 31, 2008. We did not recognize any such gain during the three months ended March 31, 2009. Our ownership in WHC decreased to 83.5% as of March 31, 2009 from 83.6% as of December 31, 2008.

Stock-Based Compensation On January 1, 2006, we adopted SFAS No. 123, (Revised 2004): Share-Based Payment (which we refer to as SFAS 123R), which replaces SFAS No. 123, Accounting for Stock-Based Compensation (which we refer to as SFAS 123) and supersedes Accounting Principles Board (which we refer to as APB) Opinion No. 25, Accounting for Stock Issued to Employees (which we refer to as APB 25). SFAS 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense over the service period (generally the vesting period) in the Consolidated Financial Statements based on their fair values. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model. The assumptions used in this model are expected dividend yield, expected volatility, risk-free interest rate and expected term. We elected to use the modified prospective transition method. Under the modified prospective transition method, awards that were granted or modified on or after January 1, 2006 are measured and accounted for in accordance with SFAS 123R. Unvested stock options and restricted stock awards that were granted prior to January 1, 2006 will continue to be accounted for in accordance with SFAS 123, using the same grant date fair value and same expense attribution method used under SFAS 123, except that all awards are recognized in the results of operations over the remaining vesting periods. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount recognized for all stock-based compensation beginning January 1, 2006. As of March 31, 2009, approximately \$18,168 and \$74,935 of unrecognized stock-based compensation expense

related to unvested awards (net of estimated forfeitures) is expected to be recognized over a

Table of Contents

weighted-average period of approximately 2.2 years and 3.3 years, related to the HLTH and WHC stock-based compensation plans, respectively.

Deferred Taxes Our deferred tax assets are comprised primarily of net operating loss carryforwards. Subject to certain limitations, these loss carryforwards may be used to offset taxable income in future periods, reducing the amount of taxes we might otherwise be required to pay. A significant portion of our deferred tax assets are reserved for through a valuation allowance. In determining the need for a valuation allowance, management determined the probability of realizing deferred tax assets, taking into consideration factors including historical operating results, expectations of future earnings and taxable income. Management will continue to evaluate the need for a valuation allowance, and in the future, should management determine that realization of the net deferred tax asset is more likely than not, some or all of the remaining valuation allowance will be reversed, and our effective tax rate may be reduced by such reversal.

Tax Contingencies Our tax contingencies are recorded to address potential exposures involving tax positions we have taken that could be challenged by tax authorities. These potential exposures result from applications of various statutes, rules, regulations and interpretations. Our estimates of tax contingencies reflect assumptions and judgments about potential actions by taxing jurisdictions. We believe that these assumptions and judgments are reasonable; however, our accruals may change in the future due to new developments in each matter and the ultimate resolution of these matters may be greater or less than the amount that we have accrued. Consistent with our historical financial reporting, we have elected to reflect interest and penalties related to uncertain tax positions as part of the income tax provision.

Table of Contents**Results of Operations**

The following table sets forth our consolidated statements of operations data and expresses that data as a percentage of revenue for the periods presented (amounts in thousands):

	Three Months Ended March 31,			
	2009		2008	
	\$	%	\$	%
Revenue	\$ 90,264	100.0	\$ 80,650	100.0
Costs and expenses:				
Cost of operations	36,565	40.5	30,927	38.3
Sales and marketing	27,561	30.5	25,149	31.2
General and administrative	21,848	24.3	20,849	25.9
Depreciation and amortization	7,103	7.9	6,775	8.4
Interest income	2,262	2.5	11,936	14.8
Interest expense	6,536	7.2	6,525	8.1
Gain on repurchases of convertible notes	6,647	7.4		
Gain on sale of EBS Master LLC			538,024	667.1
Impairment of auction rate securities			60,108	74.5
Other expense, net	269	0.3	4,144	5.1
(Loss) income from continuing operations before income tax (benefit) provision	(709)	(0.8)	476,133	590.4
Income tax (benefit) provision	(1,217)	(1.4)	25,602	31.8
Equity in earnings of EBS Master LLC			4,007	5.0
Consolidated income from continuing operations	508	0.6	454,538	563.6
Consolidated income from discontinued operations	517	0.5	3,057	3.8
Consolidated net income before noncontrolling interest	1,025	1.1	457,595	567.4
(Income) loss attributable to noncontrolling interest	(610)	(0.6)	3,845	4.8
Net income attributable to HLTH stockholders	\$ 415	0.5	\$ 461,440	572.2

Revenue is derived from advertising, sponsorship (including online CME services), e-detailing promotion and physician recruitment services, content syndication and distribution, and licenses of private online portals to employers, healthcare payers and others, along with related services including lifestyle education and personalized telephonic coaching. We also derive revenue from advertisements in *WebMD the Magazine*. Our customers include pharmaceutical, biotechnology, medical device and consumer products companies, as well as employers and health plans.

Cost of operations consists of costs related to services and products we provide to customers and costs associated with the operation and maintenance of our public and private portals. These costs relate to editorial and production, Web site operations, non-capitalized Web site development costs, and costs related to the production and distribution of our publications. These costs consist of expenses related to salaries and related expenses, non-cash stock-based

compensation, creating and licensing content, telecommunications, leased properties and printing and distribution.

Sales and marketing expense consists primarily of advertising, product and brand promotion, salaries and related expenses, and non-cash stock-based compensation. These expenses include items related to salaries and related expenses of account executives, account management and marketing personnel, costs and expenses for marketing programs, and fees for professional marketing and advertising services. Also included in sales and marketing expense are the non-cash advertising expenses discussed below.

General and administrative expense consists primarily of salaries, non-cash stock-based compensation and other salary-related expenses of administrative, finance, legal, information technology, human resources and

Table of Contents

executive personnel. These expenses include costs of general insurance and costs of accounting and internal control systems to support our operations.

Our discussions throughout MD&A make references to certain non-cash expenses. The following is a summary of our principal non-cash expenses:

Non-cash advertising expense. Expense related to the use of WebMD's prepaid advertising inventory that WHC received from News Corporation in exchange for equity instruments we issued in connection with an agreement we entered into with News Corporation in 1999 and subsequently amended in 2000. This non-cash advertising expense is included in sales and marketing expense as WebMD uses the asset for promotion of WebMD's brand.

Non-cash stock-based compensation expense. Expense related to the awards of all share-based payments to employees and non-employee directors, including grants of employee stock options. Non-cash stock-based compensation expense is reflected in the same expense captions as the related salary cost of the respective employee.

The following table is a summary of our non-cash expenses included in the respective statements of operations captions.

	Three Months Ended March 31,	
	2009	2008
Advertising expense included in:		
Sales and marketing	\$ 1,753	\$ 1,558
Stock-based compensation expense included in:		
Cost of operations	\$ 1,623	\$ 1,116
Sales and marketing	1,550	1,126
General and administrative	5,981	3,698
Consolidated income from continuing operations	9,154	5,940
Consolidated income from discontinued operations	317	343
Total stock-based compensation expense	\$ 9,471	\$ 6,283

The following discussion includes a comparison of the results of operations for the three months ended March 31, 2009 and 2008.

Revenue

Our total revenue increased 11.9% to \$90,264 from \$80,650 in the prior year period. This increase is primarily due to higher revenue from our public portals. A more detailed discussion regarding changes in revenue is included below under Results of Operations by Operating Segment.

Costs and Expenses

Cost of Operations. Cost of operations increased to \$36,565 from \$30,927 in the prior year period. As a percentage of revenue, cost of operations was 40.5% in 2009, compared to 38.3% in 2008. Included in cost of operations in 2009 was non-cash expense related to stock-based compensation of \$1,623 compared to \$1,116 in 2008. The increase in non-cash expenses during the three month period compared to last year were primarily related to stock options and restricted stock awards granted to our employees in December 2008. Cost of operations excluding such non-cash expense was \$34,942 or 38.7% of revenue, compared to \$29,811 or 37.0% of revenue last year. The increase in absolute dollars, as well as the increase as a percentage of revenue, was primarily attributable to approximately \$2,800 of higher staffing costs and approximately \$1,300 of licensing expense associated with creating and licensing content for our sponsorship arrangements and our Web sites. Additionally, the increase is related to approximately \$600 in costs related to our personalized telephonic coaching services primarily due to higher staffing levels to support that part of our business.

Table of Contents

Sales and Marketing. Sales and marketing expense increased to \$27,561 from \$25,149 in the prior year period. As a percentage of revenue, sales and marketing expense was 30.5% in 2009, compared to 31.2% in 2008. Included in sales and marketing expense in 2009 and 2008 was non-cash expense related to advertising of \$1,753 and \$1,558, respectively, and stock-based compensation of \$1,550 and \$1,126, respectively. The increase in non-cash stock-based compensation expense was primarily related to stock options and restricted stock awards granted to our employees in December 2008. Sales and marketing expense, excluding such non-cash expense, was \$24,258 or 26.9% of revenue, compared to \$22,465 or 27.9% of revenue last year. The increase in absolute dollars was primarily attributable to an increase in compensation related costs due to increased staffing and sales commissions related to higher revenue.

General and Administrative. General and administrative expense increased to \$21,848 from \$20,849 in the prior year period. As a percentage of revenue, general and administrative expenses was 24.3% in 2009, compared to 25.9% in 2008. Included in general and administrative expenses in 2009 and 2008, was non-cash stock-based compensation of \$5,981 and \$3,698. The increase in non-cash stock-based compensation expense was primarily due to stock options and restricted stock awards granted to our employees in December 2008.

General and administrative expense, excluding non-cash stock-based compensation expense discussed above, was \$15,867 or 17.6% of revenue, compared to \$17,151 or 21.3% of revenue in the prior year period. Approximately \$1,600 of the decrease in absolute dollars was attributable to lower personnel related expenses in our corporate segment as a result of lower headcount for the three months ended March 31, 2009, compared to the prior year period. This decrease was offset by an increase of approximately \$300 in our WebMD segment for the three months ended March 31, 2009, as compared to last year.

Depreciation and Amortization. Depreciation and amortization expense increased to \$7,103, compared to \$6,775 in the prior year period. The increase in depreciation and amortization expense was primarily due to approximately \$1,000 increase in depreciation expense relating to capital expenditures in 2008 and 2009 in our WebMD segment, partially offset by a decrease in amortization expense of approximately \$700 related to certain intangible assets becoming fully amortized.

Interest Income. Interest income decreased to \$2,262 from \$11,936 in the prior year period. The decrease was due to lower average rates of return and lower average investment balances during the three months ended March 31, 2009, as compared to the prior year period.

Interest Expense. Interest expense of \$6,536 was consistent with interest expense of \$6,525 in the prior year period. Interest expense in the three months ended March 31, 2009 and 2008 included \$2,799 and \$2,661, respectively, related to the amortization of the debt discount for our 31/8% Notes and the amortization of the debt issuance costs for both our 1.75% Notes and our 31/8% Notes.

Gain on Repurchases of Convertible Notes. During the three months ended March 31, 2009, we repurchased \$76,517 principal amount of our 1.75% Convertible Notes for \$71,623 and \$18,000 principal amount of our 31/8% Convertible Notes for \$15,044. We recognized a net gain on the repurchase of these notes of \$6,647 which considers the write-off of the related portion of unamortized deferred issuance costs.

Gain on Sale of EBS Master LLC. The gain on sale of EBS Master LLC of \$538,024 for the three months ended March 31, 2008 represented a gain recognized in connection with the sale of our equity investment in EBS Master LLC.

Impairment of Auction Rate Securities. Impairment of auction rate securities represents a charge of \$60,108 related to an other-than temporary reduction of the fair value of our auction rate securities during the three months ended March 31, 2008.

Other Expense, Net. Other expense, net was \$269, compared to \$4,144 in the prior year period. Included in other expense, net was \$578 and \$372 for the three months ended March 31, 2009 and 2008, respectively, of external legal costs and expenses we incurred related to the investigation by the United States Attorney for the District of South Carolina and the SEC and \$245 and \$437 for the three months ended March 31, 2009 and 2008, respectively, related to the reversal of certain sales and use tax contingencies resulting from the expiration of various statutes of limitations. Also included in other expense, net for the three months ended

Table of Contents

March 31, 2008 was \$4,259 of advisory expenses for professional fees, primarily consisting of legal, accounting and financial advisory services related to the potential merger transaction with WHC, which was terminated in October 2008.

Income Tax (Benefit) Provision. The income tax benefit of \$1,217 and provision of \$25,602 for the three months ended March 31, 2009 and 2008, respectively, represents taxes for federal, state and other jurisdictions. For the three months ended March 31, 2009, the gain on repurchases of convertible notes is provided for at a lower effective tax rate than our ordinary operations, resulting in an income tax benefit. For the three months ended March 31, 2008, while the majority of the gain on the 2008 sale of EBS Master LLC was offset by net operating loss carryforwards, certain alternative minimum taxes and other state taxes were not offset, representing approximately \$24,000 of the income tax provision. Also, the income tax provision for the three months ended March 31, 2008 excludes a benefit for the impairment of ARS, as it is currently not deductible for tax purposes.

Consolidated Income from Discontinued Operations, Net of Tax. Income from discontinued operations was \$517 and \$3,057 for the three months ended March 31, 2009 and 2008. Income from discontinued operations primarily represents the net operating results of our Porex segment and LBB for the three months ended March 31, 2009 and March 31, 2008, as well as the net operating results for our ViPS segment for the three months ended March 31, 2008.

(Income) Loss Attributable to Noncontrolling Interest. Noncontrolling interest expense of \$610 for the three months ended March 31, 2009, compared to income of \$3,845 in the prior year period, represents the noncontrolling stockholders' proportionate share of net income (loss) for WHC. (Income) loss attributable to noncontrolling interest fluctuates based on the net income or loss reported by WHC, combined with changes in the percentage ownership of WHC held by the noncontrolling shareholders.

Net Income Attributable To HLTH Stockholders. Net income attributable HLTH stockholders was \$415 for the three months ended March 31, 2009, compared to \$461,440 in the prior year period. Net income attributable to HLTH stockholders was significantly higher in the prior year period, due to the gain on sale of EBS Master LLC, offset by an impairment charge of \$60,108 related to our ARS.

Results of Operations by Operating Segment

We monitor the performance of our segments based on earnings before interest, taxes, non-cash and other items. Other items include: a gain on the repurchases of our convertible notes; a gain on the sale of our investment in EBS; an impairment charge related to investments in auction rate securities; legal expenses we incurred, which reflect costs and expenses related to the investigation by the United States Attorney for the District of South Carolina and the SEC; income related to the reduction of certain sales and use tax contingencies; and professional fees, primarily consisting of legal, accounting and financial advisory services, related to the merger between HLTH and WHC, which was terminated in October 2008.

Table of Contents

Summarized financial information for our WebMD segment and Corporate segment and a reconciliation to consolidated income from continuing operations is presented below:

	Three Months Ended March 31,	
	2009	2008
Revenue		
WebMD:		
Advertising and sponsorship	\$ 65,428	\$ 56,482
Licensing	22,975	21,923
Print	1,861	2,245
	\$ 90,264	\$ 80,650
Earnings before interest, taxes, non-cash and other items		
WebMD	\$ 18,688	\$ 16,332
Corporate	(3,427)	(5,059)
	15,261	11,273
Interest, taxes, non-cash and other items		
Interest income	2,262	11,936
Interest expense	(6,536)	(6,525)
Income tax benefit (provision)	1,217	(25,602)
Depreciation and amortization	(7,103)	(6,775)
Non-cash stock-based compensation	(9,154)	(5,940)
Non-cash advertising	(1,753)	(1,558)
Gain on repurchases of convertible notes	6,647	
Equity in earnings of EBS Master LLC		4,007
Gain on sale of EBS Master LLC		538,024
Impairment of auction rate securities		(60,108)
Other expense, net	(333)	(4,194)
Consolidated income from continuing operations	508	454,538
Consolidated income from discontinued operations, net of tax	517	3,057
Consolidated net income before noncontrolling interest	1,025	457,595
(Income) loss attributable to noncontrolling interest	(610)	3,845
Net income attributable to HLTH Corporation	\$ 415	\$ 461,440

The following discussion is a comparison of the results of operations for our WebMD segment and Corporate segment for the three months ended March 31, 2009 to the three months ended March 31, 2008:

WebMD*Revenue.*

Advertising and Sponsorship. Advertising and sponsorship revenue increased \$8,946 or 15.8% compared to the prior year period. The increase in advertising and sponsorship revenue was primarily attributable to an increase in the number of brands and sponsored programs promoted on our sites. The number of such programs grew to 751 compared to 628 in the prior year period. In general, pricing remained relatively stable for our online advertising programs and was not a significant source of the revenue increase. Substantially all of our advertising and sponsorship revenue is generated through our public portals.

Table of Contents

Licensing. Licensing revenue increased \$1,052 or 4.8% compared to the prior year period. This increase was due to an increase in the number of companies using our private portal platform to 134 from 122 in the prior year period. In general, pricing remained relatively stable for our private portal licenses and was not a significant source of the revenue increase. We also have approximately 140 additional customers who purchase stand-alone decision support services from us. Substantially all of our advertising and sponsorship revenue is generated through our public portals.

Print. Print revenue was \$1,861 compared to \$2,245 in the prior year period, a decrease of \$384. *WebMD the Magazine* and other print products are reflected in print revenue.

Earnings Before Interest, Taxes, Non-Cash and Other Items. Earnings before interest, taxes, non-cash and other items was \$18,688 or 20.7% of revenue, compared to \$16,332 or 20.3% of revenue in the prior year period. This increase as a percentage of revenue was primarily due to higher revenue from the increase in number of brands and sponsored programs in our public portals as well as the increase in companies using our private online portal, without incurring a proportionate increase in overall expenses.

Corporate

Earnings Before Interest, Taxes, Non-Cash and Other Items. Corporate expenses decreased to \$3,427 or 3.8% of revenue, compared to \$5,059 or 6.3% of revenue in the prior year period. The decrease in our Corporate segment, in whole dollars, is primarily due to lower personnel related expenses due to lower headcount during the three months ended March 31, 2009, lower professional services fees and lower insurance expenses reflecting the continued decrease in our corporate infrastructure.

Liquidity and Capital Resources

Cash used in operating activities from our continuing operations was \$2,691 for the three months ended March 31, 2009, compared to cash provided by operating activities from our continuing operations of \$44,333 for the prior year period. The \$47,024 decrease in cash flow from continuing operations as compared to a year ago relates to changes in working capital which can be impacted by the timing of the cutoff of compensation accruals, payments of annual insurance premiums, other expense accruals, the billing and collection of receivables from our customers and the timing of estimated tax payments in relation to the quarter's end.

Cash used in investing activities from our continuing operations was \$4,459 for the three months ended March 31, 2009, compared to cash provided by operating activities from our continuing operations of \$524,847 for the prior year period. Cash provided by investing activities from our continuing operations for the three months ended March 31, 2008 included \$574,617 of proceeds received from the 2008 EBSCO Sale, as well as the \$23,333 we received, which was released from escrow, from the sale of our EPS segment, which was sold in the later part of 2006. Also included in cash provided by investing activities from our continuing operations for the three months ended March 31, 2009 are proceeds of \$600 from sales of our available for sale securities, compared to net disbursements of \$72,632 from purchases, net of maturities and sales, in the prior year period.

Cash used in financing activities from our continuing operations was \$71,142 for the three months ended March 31, 2009, compared to cash provided by financing activities from our continuing operations of \$1,777 for the prior year period. Cash used in financing activities for the three months ended March 31, 2009 included \$78,183 in cash paid to repurchase a portion of our 1.75% Notes and 3¹/₈% Notes. In addition, cash used in financing activities for the three months ended March 31, 2009 and 2008, included proceeds of \$7,041 and \$1,777, respectively, from the issuance of HLTH Common Stock and WHC Class A Common Stock resulting from the exercises of employee stock options.

Included in our consolidated statements of cash flows are cash flows from discontinued operations of our ViPS segment, Porex segment and LBB. Our cash flows provided by operating activities from discontinued operations for the three months ended March 31, 2009 included an aggregate of \$5,881 related to our Porex segment and LBB business, respectively, while cash flows provided by operating activities from discontinued operations for the three months ended March 31, 2008 included an aggregate of \$4,799 related to our ViPS

Table of Contents

segment, Porex segment and LBB. Also, included in cash flows from discontinued operations used in operating activities for the three months ended March 31, 2009 and 2008 is \$3,880 and \$6,765, respectively in payments made in connection with legal costs and expenses incurred related to the investigation by the United States Attorney for the District of South Carolina and the SEC, net of the receipt of insurance reimbursements related to our Director & Officer Liability Insurance Coverage during the three months ended March 31, 2009.

As of March 31, 2009, we had \$552,483 in consolidated cash and cash equivalents, and we owned investments in ARS with a face value of \$354,400 and a fair value of \$274,069. While liquidity for our ARS investments is currently limited, HLTH recently entered into a new non-recourse credit facility with Citigroup and WebMD recently entered into an amended non-recourse credit facility with Citigroup in April 2009 that will allow each of us to borrow up to 75% of the face amount of our ARS holdings through April 2010. See Introduction Background Information on Certain Trends and Developments Non-Recourse Credit Facilities and Critical Accounting Estimates and Policies Fair Value of Investments. Potential future cash commitments include our anticipated 2009 capital expenditure requirements for the full year which we currently estimate to be up to \$25,000. Our anticipated capital expenditures relate to improvements that will be deployed across WebMD's public and private portal web sites in order to enable us to service future growth in unique users, page views and private portal customers, as well as to create new sponsorship areas for our customers.

Based on our plans and expectations as of the date of this Quarterly Report and taking into consideration issues relating to the liquidity of our ARS investments, we believe that our available cash resources and future cash flow from operations will provide sufficient cash resources to meet the cash commitments of our 1.75% Notes and our 31/8% Notes and to fund our currently anticipated working capital and capital expenditure requirements for up to twenty-four months. Our future liquidity and capital requirements will depend upon numerous factors, including retention of customers at current volume and revenue levels, our existing and new application and service offerings, competing technological and market developments, and potential future acquisitions. In addition, our ability to generate cash flow is subject to numerous factors beyond our control, including general economic, regulatory and other matters affecting us and our customers. We plan to continue to enhance the relevance of our online services to our audience and sponsors and will continue to invest in acquisitions, strategic relationships, facilities and technological infrastructure and product development. We intend to grow each of our existing businesses and enter into complementary ones through both internal investments and acquisitions. We may need to raise additional funds to support expansion, develop new or enhanced applications and services, respond to competitive pressures, acquire complementary businesses or technologies or take advantage of unanticipated opportunities. If required, we may raise such additional funds through public or private debt or equity financing, strategic relationships or other arrangements. We cannot assure you that such financing will be available on acceptable terms, if at all, or that such financing will not be dilutive to our stockholders. Future indebtedness may impose various restrictions and covenants on us that could limit our ability to respond to market conditions, to provide for unanticipated capital investments or to take advantage of business opportunities.

Recent Accounting Pronouncements.

In April 2009, the Financial Accounting Standards Board (which we refer to as FASB) issued Staff Position No. FAS 107-1 and APB 28-1, Interim Disclosures about Fair Value of Financial Instruments (which we refer to as FSP FAS 107-1). FSP FAS 107-1 amends SFAS No. 107, Disclosures about Fair Value of Financial Instruments, and requires disclosures about fair value of financial instruments in interim reporting periods. Such disclosures were previously required only in annual financial statements. FSP FAS 107-1 is effective for interim and annual reporting periods ending after June 15, 2009. The adoption of FSP FAS 107-1 is only expected to apply to financial statement disclosures.

In April 2009, the FASB issued Staff Position No. FAS 157-4. Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly (which we refer to as FSP FAS 157-4). FSP 157-4 provides additional guidance for estimating fair value in accordance with FASB Statement No. 157, Fair Value Measurement, when the volume and level of activity for the asset or liability have significantly decreased, as well as guidance on

Table of Contents

identifying circumstances that indicate a transaction is not orderly. FSP FAS 157-4 is effective for interim and annual reporting periods ending after June 15, 2009 and shall be applied prospectively. We are currently evaluating the requirements of this pronouncement and have not determined the impact, if any that the adoption will have on our consolidated financial statements.

In April 2009, the FASB issued Staff Position No. FAS 115-2 and FAS 124-2, Recognition and Presentation of Other-Than-Temporary Impairments (which we refer to as FSP FAS 115-2). FSP FAS 115-2 provides additional guidance to make other-than-temporary impairments more operational and to improve the financial statement presentation of such impairments. FSP FAS 115-2 is effective for interim and annual reporting periods ending after June 15, 2009. We are currently evaluating the requirements of this pronouncement and have not determined the impact, if any that the adoption will have on our consolidated financial statements.

Factors That May Affect Our Future Financial Condition or Results of Operations

This section describes circumstances or events that could have a negative effect on our financial results or operations or that could change, for the worse, existing trends in some or all of our businesses. The occurrence of one or more of the circumstances or events described below could have a material adverse effect on our financial condition, results of operations and cash flows or on the trading prices of the common stock and convertible notes that we have issued or securities we may issue in the future. The risks and uncertainties described in this Quarterly Report are not the only ones facing us. Additional risks and uncertainties that are not currently known to us or that we currently believe are immaterial may also adversely affect our business and operations.

Risks Related to Our WebMD Operations and the Healthcare Content We Provide

If we are unable to provide content and services that attract and retain users to The WebMD Health Network on a consistent basis, our advertising and sponsorship revenue could be reduced

Users of *The WebMD Health Network* have numerous other online and offline sources of healthcare information services. Our ability to compete for user traffic on our public portals depends upon our ability to make available a variety of health and medical content, decision-support applications and other services that meet the needs of a variety of types of users, including consumers, physicians and other healthcare professionals, with a variety of reasons for seeking information. Our ability to do so depends, in turn, on:

our ability to hire and retain qualified authors, journalists and independent writers;

our ability to license quality content from third parties; and

our ability to monitor and respond to increases and decreases in user interest in specific topics.

We cannot assure you that we will be able to continue to develop or acquire needed content, applications and tools at a reasonable cost. In addition, since consumer users of our public portals may be attracted to *The WebMD Health Network* as a result of a specific condition or for a specific purpose, it is difficult for us to predict the rate at which they will return to the public portals. Because we generate revenue by, among other things, selling sponsorships of specific pages, sections or events on *The WebMD Health Network*, a decline in user traffic levels or a reduction in the number of pages viewed by users could cause our revenue to decrease and could have a material adverse effect on our results of operations.

Developing and implementing new and updated applications, features and services for our public and private portals may be more difficult than expected, may take longer and cost more than expected and may not result in sufficient increases in revenue to justify the costs

Attracting and retaining users of our public portals and clients for our private portals requires us to continue to improve the technology underlying those portals and to continue to develop new and updated applications, features and services for those portals. If we are unable to do so on a timely basis or if we are unable to implement new applications, features and services without disruption to our existing ones, we may lose potential users and clients.

Table of Contents

We rely on a combination of internal development, strategic relationships, licensing and acquisitions to develop our portals and related applications, features and services. Our development and/or implementation of new technologies, applications, features and services may cost more than expected, may take longer than originally expected, may require more testing than originally anticipated and may require the acquisition of additional personnel and other resources. There can be no assurance that the revenue opportunities from any new or updated technologies, applications, features or services will justify the amounts spent.

We face significant competition for our healthcare information products and services

The markets for healthcare information products and services are intensely competitive, continually evolving and, in some cases, subject to rapid change.

Our public portals face competition from numerous other companies, both in attracting users and in generating revenue from advertisers and sponsors. We compete for users with online services and Web sites that provide health-related information, including both commercial sites and not-for-profit sites. We compete for advertisers and sponsors with: health-related Web sites; general purpose consumer Web sites that offer specialized health sub-channels; other high-traffic Web sites that include both healthcare-related and non-healthcare-related content and services; search engines that provide specialized health search; and advertising networks that aggregate traffic from multiple sites. Our public portals also face competition from offline publications and information services.

Our private portals compete with: providers of healthcare decision-support tools and online health management applications, including personal health records; wellness and disease management vendors; and health information services and health management offerings of healthcare benefits companies and their affiliates.

Many of our competitors have greater financial, technical, product development, marketing and other resources than we do. These organizations may be better known than we are and have more customers or users than we do. We cannot provide assurance that we will be able to compete successfully against these organizations or any alliances they have formed or may form. Since there are no substantial barriers to entry into the markets in which our public portals participate, we expect that competitors will continue to enter these markets.

Failure to maintain and enhance the WebMD brand could have a material adverse effect on our business

We believe that the WebMD brand identity that we have developed has contributed to the success of our business and has helped us achieve recognition as a trusted source of health and wellness information. We also believe that maintaining and enhancing that brand is important to expanding the user base for our public portals, to our relationships with sponsors and advertisers and to our ability to gain additional employer and healthcare payer clients for our private portals. We have expended considerable resources on establishing and enhancing the WebMD brand and our other brands, and we have developed policies and procedures designed to preserve and enhance our brands, including editorial procedures designed to provide quality control of the information we publish. We expect to continue to devote resources and efforts to maintain and enhance our brands. However, we may not be able to successfully maintain or enhance awareness of our brands, and events outside of our control may have a negative effect on our brands. If we are unable to maintain or enhance awareness of our brand, and do so in a cost-effective manner, our business could be adversely affected.

Our online businesses have a limited operating history

Our online businesses have a limited operating history and participate in relatively new markets. These markets, and our online businesses, have undergone significant changes during their short history and can be expected to continue

to change. Many companies with business plans based on providing healthcare information and related services through the Internet have failed to be profitable and some have filed for bankruptcy and/or ceased operations. Even if demand from users exists, we cannot assure you that our businesses will continue to be profitable.

Table of Contents

Our failure to attract and retain qualified executives and employees may have a material adverse effect on our business

Our business depends largely on the skills, experience and performance of key members of our management team. We also depend, in part, on our ability to attract and retain qualified writers and editors, software developers and other technical personnel and sales and marketing personnel. Competition for qualified personnel in the healthcare information services and Internet industries is intense. We cannot assure you that we will be able to hire or retain a sufficient number of qualified personnel to meet our requirements, or that we will be able to do so at salary and benefit costs that are acceptable to us. Failure to do so may have an adverse effect on our business.

The timing of our advertising and sponsorship revenue may vary significantly from quarter to quarter and is subject to factors beyond our control, including regulatory changes affecting advertising and promotion of drugs and medical devices and general economic conditions

Our advertising and sponsorship revenue, which accounted for approximately 75% of our total revenue for the year ended December 31, 2008, may vary significantly from quarter to quarter due to a number of factors, many of which are not in our control, and some of which may be difficult to forecast accurately, including potential effects on demand for our services as a result of regulatory changes affecting advertising and promotion of drugs and medical devices and general economic conditions. The majority of our advertising and sponsorship programs are for terms of approximately four to twelve months. We have relatively few longer term advertising and sponsorship programs. We cannot assure you that our current advertisers and sponsors will continue to use our services beyond the terms of their existing contracts or that they will enter into any additional contracts.

The time between the date of initial contact with a potential advertiser or sponsor regarding a specific program and the execution of a contract with the advertiser or sponsor for that program may be lengthy, especially for larger contracts, and may be subject to delays over which we have little or no control, including as a result of budgetary constraints of the advertiser or sponsor or their need for internal approvals. Other factors that could affect the timing of contracting for specific programs with advertisers and sponsors, or receipt of revenue under such contracts, include:

- the timing of FDA approval for new products or for new approved uses for existing products;
- the timing of FDA approval of generic products that compete with existing brand name products;
- the timing of withdrawals of products from the market;
- the timing of rollouts of new or enhanced services on our public portals;
- seasonal factors relating to the prevalence of specific health conditions and other seasonal factors that may affect the timing of promotional campaigns for specific products; and
- the scheduling of conferences for physicians and other healthcare professionals.

We may be unsuccessful in our efforts to increase advertising and sponsorship revenue from consumer products companies

Most of our advertising and sponsorship revenue has, in the past, come from pharmaceutical, biotechnology and medical device companies. We have been focusing on increasing sponsorship revenue from consumer products companies that are interested in communicating health-related or safety-related information about their products to our audience. However, many consumer products companies have increased the portion of their promotional spending

used on the Internet, we cannot assure you that these advertisers and sponsors will find our consumer Web sites to be as effective as other Web sites or traditional media for promoting their products and services. If we encounter difficulties in competing with the other alternatives available to consumer products companies, this portion of our business may develop more slowly than we expect or may fail to develop. In addition, revenues from consumer products companies are more likely to reflect general

Table of Contents

economic conditions, and to be reduced to a greater extent during economic downturns or recessions, than revenues from pharmaceutical, biotechnology and medical device companies.

Lengthy sales and implementation cycles for our private online portals make it difficult to forecast our revenues from these applications and may have an adverse impact on our business

The period from our initial contact with a potential client for a private online portal and the first purchase of our solution by the client is difficult to predict. In the past, this period has generally ranged from six to twelve months, but in some cases has been longer. Potential sales may be subject to delays or cancellations due to a client's internal procedures for approving large expenditures and other factors beyond our control, including the effect of general economic conditions on the willingness of potential clients to commit to licensing our private portals. The time it takes to implement a private online portal is also difficult to predict and has lasted as long as six months from contract execution to the commencement of live operation. Implementation may be subject to delays based on the availability of the internal resources of the client that are needed and other factors outside of our control. As a result, we have limited ability to forecast the timing of revenue from new clients. This, in turn, makes it more difficult to predict our financial performance from quarter to quarter.

During the sales cycle and the implementation period, we may expend substantial time, effort and money preparing contract proposals, negotiating contracts and implementing the private online portal without receiving any related revenue. In addition, many of the expenses related to providing private online portals are relatively fixed in the short term, including personnel costs and technology and infrastructure costs. Even if our private portal revenue is lower than expected, we may not be able to reduce related short-term spending in response. Any shortfall in such revenue would have a direct impact on our results of operations.

Our ability to provide comparative information on hospital cost and quality depends on our ability to obtain the required data on a timely basis and, if we are unable to do so, our private portal services would be less attractive to clients

We provide, in connection with our private portal services, comparative information about hospital cost and quality. Our ability to provide this information depends on our ability to obtain comprehensive, reliable data. We currently obtain this data from a number of public and private sources, including the Centers for Medicare and Medicaid Services (CMS), many individual states and the Leapfrog Group. We cannot provide assurance that we would be able to find alternative sources for this data on acceptable terms and conditions. Accordingly, our business could be negatively impacted if CMS or our other data sources cease to make such information available or impose terms and conditions for making it available that are not consistent with our planned usage. In addition, the quality of the comparative information services we provide depends on the reliability of the information that we are able to obtain. If the information we use to provide these services contains errors or is otherwise unreliable, we could lose clients and our reputation could be damaged.

Our ability to renew existing licenses with employers and health plans will depend, in part, on our ability to continue to increase usage of our private portal services by their employees and plan members

In a healthcare market where a greater share of the responsibility for healthcare costs and decision-making has been increasingly shifting to consumers, use of information technology (including personal health records) to assist consumers in making informed decisions about healthcare has also increased. We believe that through our WebMD Health and Benefits Manager platform, including our personal health record application, we are well positioned to play a role in this consumer-directed healthcare environment, and these services will be a significant driver for the growth of our private portals during the next several years. However, our growth strategy depends, in part, on increasing usage of our private portal services by our employer and health plan clients' employees and members,

respectively. Increasing usage of our services requires us to continue to deliver and improve the underlying technology and develop new and updated applications, features and services. In addition, we face competition in the area of healthcare decision-support tools and online health management applications and health information services. Many of our competitors have greater financial, technical, product development, marketing and other resources than we do, and may be better known than we

Table of Contents

are. We cannot provide assurance that we will be able to meet our development and implementation goals, nor that we will be able to compete successfully against other vendors offering competitive services and, as a result, may experience static or diminished usage for our private portal services and possible non-renewals of our license agreements.

We may be subject to claims brought against us as a result of content we provide

Consumers access health-related information through our online services, including information regarding particular medical conditions and possible adverse reactions or side effects from medications. If our content, or content we obtain from third parties, contains inaccuracies, it is possible that consumers, employees, health plan members or others may sue us for various causes of action. Although our Web sites contain terms and conditions, including disclaimers of liability, that are intended to reduce or eliminate our liability, the law governing the validity and enforceability of online agreements and other electronic transactions is evolving. We could be subject to claims by third parties that our online agreements with consumers and physicians that provide the terms and conditions for use of our public or private portals are unenforceable. A finding by a court that these agreements are invalid and that we are subject to liability could harm our business and require costly changes to our business.

We have editorial procedures in place to provide quality control of the information that we publish or provide. However, we cannot assure you that our editorial and other quality control procedures will be sufficient to ensure that there are no errors or omissions in particular content. Even if potential claims do not result in liability to us, investigating and defending against these claims could be expensive and time consuming and could divert management's attention away from our operations. In addition, our business is based on establishing the reputation of our portals as trustworthy and dependable sources of healthcare information. Allegations of impropriety or inaccuracy, even if unfounded, could harm our reputation and business.

Expansion to markets outside the United States will subject us to additional risks

One element of our growth strategy is to seek to expand our online services to markets outside the United States. Generally, we expect that we would accomplish this through partnerships or joint ventures with other companies having expertise in the specific country or region. However, our participation in international markets will still be subject to certain risks beyond those applicable to our operations in the United States, such as:

difficulties in staffing and managing operations outside of the United States;

fluctuations in currency exchange rates;

burdens of complying with a wide variety of legal, regulatory and market requirements;

variability of economic and political conditions, including the extent of the impact of recent adverse economic conditions in markets outside the United States;

tariffs or other trade barriers;

costs of providing and marketing products and services in different markets;

potentially adverse tax consequences, including restrictions on repatriation of earnings; and

difficulties in protecting intellectual property.

Table of Contents

Risks Related to the Internet and Our Technological Infrastructure

Any service interruption or failure in the systems that we use to provide online services could harm our business

Our online services are designed to operate 24 hours a day, seven days a week, without interruption. However, we have experienced and expect that we will in the future experience interruptions and delays in services and availability from time to time. We rely on internal systems as well as third-party vendors, including data center providers and bandwidth providers, to provide our online services. We may not maintain redundant systems or facilities for some of these services. In the event of a catastrophic event with respect to one or more of these systems or facilities, we may experience an extended period of system unavailability, which could negatively impact our relationship with users. In addition, system failures may result in loss of data, including user registration data, content, and other data critical to the operation of our online services, which could cause significant harm to our business and our reputation.

To operate without interruption or loss of data, both we and our service providers must guard against:

- damage from fire, power loss and other natural disasters;
- communications failures;
- software and hardware errors, failures and crashes;
- security breaches, computer viruses and similar disruptive problems; and
- other potential service interruptions.

Any disruption in the network access or co-location services provided by third-party providers to us or any failure by these third-party providers or our own systems to handle current or higher volume of use could significantly harm our business. We exercise little control over these third-party vendors, which increases our vulnerability to problems with services they provide.

Any errors, failures, interruptions or delays experienced in connection with these third-party technologies and information services or our own systems could negatively impact our relationships with users and adversely affect our brand and our business and could expose us to liabilities to third parties. Although we maintain insurance for our business, the coverage under our policies may not be adequate to compensate us for all losses that may occur. In addition, we cannot provide assurance that we will continue to be able to obtain adequate insurance coverage at an acceptable cost.

Implementation of additions to or changes in hardware and software platforms used to deliver our online services may result in performance problems and may not provide the additional functionality that was expected

From time to time, we implement additions to or changes in the hardware and software platforms we use for providing our online services. During and after the implementation of additions or changes, a platform may not perform as expected, which could result in interruptions in operations, an increase in response time or an inability to track performance metrics. In addition, in connection with integrating acquired businesses, we may move their operations to our hardware and software platforms or make other changes, any of which could result in interruptions in those operations. Any significant interruption in our ability to operate any of our online services could have an adverse effect on our relationships with users and clients and, as a result, on our financial results. We rely on a combination of purchasing, licensing, internal development, and acquisitions to develop our hardware and software platforms. Our implementation of additions to or changes in these platforms may cost more than originally expected, may take longer

than originally expected, and may require more testing than originally anticipated. In addition, we cannot provide assurance that additions to or changes in these platforms will provide the additional functionality and other benefits that were originally expected.

Table of Contents

If the systems we use to provide online portals experience security breaches or are otherwise perceived to be insecure, our business could suffer

We retain and transmit confidential information, including personal health records, in the processing centers and other facilities we use to provide online services. It is critical that these facilities and infrastructure remain secure and be perceived by the marketplace as secure. A security breach could damage our reputation or result in liability. We may be required to expend significant capital and other resources to protect against security breaches and hackers or to alleviate problems caused by breaches. Despite the implementation of security measures, this infrastructure or other systems that we interface with, including the Internet and related systems, may be vulnerable to physical break-ins, hackers, improper employee or contractor access, computer viruses, programming errors, denial-of-service attacks or other attacks by third parties or similar disruptive problems. Any compromise of our security, whether as a result of our own systems or the systems that they interface with, could reduce demand for our services and could subject us to legal claims from our clients and users, including for breach of contract or breach of warranty.

Our online services are dependent on the development and maintenance of the Internet infrastructure

Our ability to deliver our online services is dependent on the development and maintenance of the infrastructure of the Internet by third parties. The Internet has experienced a variety of outages and other delays as a result of damages to portions of its infrastructure, and it could face outages and delays in the future. The Internet has also experienced, and is likely to continue to experience, significant growth in the number of users and the amount of traffic. If the Internet continues to experience increased usage, the Internet infrastructure may be unable to support the demands placed on it. In addition, the reliability and performance of the Internet may be harmed by increased usage or by denial-of-service attacks. Any resulting interruptions in our services or increases in response time could, if significant, result in a loss of potential or existing users of and advertisers and sponsors on our Web sites and, if sustained or repeated, could reduce the attractiveness of our services.

Customers who utilize our online services depend on Internet service providers and other Web site operators for access to our Web sites. All of these providers have experienced significant outages in the past and could experience outages, delays and other difficulties in the future due to system failures unrelated to our systems. Any such outages or other failures on their part could reduce traffic to our Web sites.

Third parties may challenge the enforceability of our online agreements

The law governing the validity and enforceability of online agreements and other electronic transactions is evolving. We could be subject to claims by third parties that the online terms and conditions for use of our Web sites, including disclaimers or limitations of liability, are unenforceable. A finding by a court that these terms and conditions or other online agreements are invalid could harm our business.

We could be subject to breach of warranty or other claims by clients of our online portals if the software and systems we use to provide them contain errors or experience failures

Errors in the software and systems we use could cause serious problems for clients of our online portals. We may fail to meet contractual performance standards or client expectations. Clients of our online portals may seek compensation from us or may seek to terminate their agreements with us, withhold payments due to us, seek refunds from us of part or all of the fees charged under those agreements or initiate litigation or other dispute resolution procedures. In addition, we could face breach of warranty or other claims by clients or additional development costs. Our software and systems are inherently complex and, despite testing and quality control, we cannot be certain that they will perform as planned.

We attempt to limit, by contract, our liability to our clients for damages arising from our negligence, errors or mistakes. However, contractual limitations on liability may not be enforceable in certain circumstances or may otherwise not provide sufficient protection to us from liability for damages. We maintain liability insurance coverage, including coverage for errors and omissions. However, it is possible that claims could exceed the amount of our applicable insurance coverage, if any, or that this coverage may not continue

Table of Contents

to be available on acceptable terms or in sufficient amounts. Even if these claims do not result in liability to us, investigating and defending against them would be expensive and time consuming and could divert management's attention away from our operations. In addition, negative publicity caused by these events may delay or hinder market acceptance of our services, including unrelated services.

Risks Related to the Healthcare Industry, Healthcare Regulation and Internet Regulation

Developments in the healthcare industry could adversely affect our business

Most of our revenue is derived from the healthcare industry and could be affected by changes affecting healthcare spending. We are particularly dependent on pharmaceutical, biotechnology and medical device companies for our advertising and sponsorship revenue. General reductions in expenditures by healthcare industry participants could result from, among other things:

government regulation or private initiatives that affect the manner in which healthcare providers interact with patients, payers or other healthcare industry participants, including changes in pricing or means of delivery of healthcare products and services;

consolidation of healthcare industry participants;

reductions in governmental funding for healthcare; and

adverse changes in business or economic conditions affecting healthcare payers or providers, pharmaceutical, biotechnology or medical device companies or other healthcare industry participants.

Even if general expenditures by industry participants remain the same or increase, developments in the healthcare industry may result in reduced spending in some or all of the specific market segments that we serve or are planning to serve. For example, use of our products and services could be affected by:

changes in the design of health insurance plans;

a decrease in the number of new drugs or medical devices coming to market; and

decreases in marketing expenditures by pharmaceutical or medical device companies, including as a result of governmental regulation or private initiatives that discourage or prohibit advertising or sponsorship activities by pharmaceutical or medical device companies.

In addition, our customers' expectations regarding pending or potential industry developments may also affect their budgeting processes and spending plans with respect to products and services of the types we provide.

The healthcare industry has changed significantly in recent years and we expect that significant changes will continue to occur. However, the timing and impact of developments in the healthcare industry are difficult to predict. We cannot assure you that the markets for our products and services will continue to exist at current levels or that we will have adequate technical, financial and marketing resources to react to changes in those markets.

Government regulation of healthcare creates risks and challenges with respect to our compliance efforts and our business strategies

The healthcare industry is highly regulated and is subject to changing political, legislative, regulatory and other influences. Existing and new laws and regulations affecting the healthcare industry could create unexpected liabilities for us, could cause us to incur additional costs and could restrict our operations. Many healthcare laws are complex, and their application to specific products and services may not be clear. In particular, many existing healthcare laws and regulations, when enacted, did not anticipate the healthcare information services that we provide. However, these laws and regulations may nonetheless be applied to our products and services. Our failure to accurately anticipate the application of these laws and regulations, or

Table of Contents

other failure to comply, could create liability for us, result in adverse publicity and negatively affect our businesses. Some of the risks we face from healthcare regulation are as follows:

Regulation of Drug and Medical Device Advertising and Promotion. The WebMD Health Network provides services involving advertising and promotion of prescription and over-the-counter drugs and medical devices. If the Food and Drug Administration (FDA) or the Federal Trade Commission (FTC) finds that any information on *The WebMD Health Network* or in *WebMD the Magazine* violates FDA or FTC regulations, they may take regulatory or judicial action against us and/or the advertiser or sponsor of that information. State attorneys general may also take similar action based on their state's consumer protection statutes. Any increase or change in regulation of drug or medical device advertising and promotion could make it more difficult for us to contract for sponsorships and advertising. Members of Congress, physician groups and others have criticized the FDA's current policies, and have called for restrictions on advertising of prescription drugs to consumers and increased FDA enforcement. We cannot predict what actions the FDA or industry participants may take in response to these criticisms. It is also possible that new laws would be enacted that impose restrictions on such advertising. In addition, recent private industry initiatives have resulted in voluntary restrictions, which advertisers and sponsors have agreed to follow. Our advertising and sponsorship revenue could be materially reduced by additional restrictions on the advertising of prescription drugs and medical devices to consumers, whether imposed by law or regulation or required under policies adopted by industry members.

Anti-kickback Laws. There are federal and state laws that govern patient referrals, physician financial relationships and inducements to healthcare providers and patients. The federal healthcare programs anti-kickback law prohibits any person or entity from offering, paying, soliciting or receiving anything of value, directly or indirectly, for the referral of patients covered by Medicare, Medicaid and other federal healthcare programs or the leasing, purchasing, ordering or arranging for or recommending the lease, purchase or order of any item, good, facility or service covered by these programs. Many states also have similar anti-kickback laws that are not necessarily limited to items or services for which payment is made by a federal healthcare program. These laws are applicable to manufacturers and distributors and, therefore, may restrict how we and some of our customers market products to healthcare providers, including e-details. Any determination by a state or federal regulatory agency that any of our practices violate any of these laws could subject us to civil or criminal penalties and require us to change or terminate some portions of our business and could have an adverse effect on our business. Even an unsuccessful challenge by regulatory authorities of our practices could result in adverse publicity and be costly for us to respond to.

Medical Professional Regulation. The practice of most healthcare professions requires licensing under applicable state law. In addition, the laws in some states prohibit business entities from practicing medicine. If a state determines that some portion of our business violates these laws, it may seek to have us discontinue those portions or subject us to penalties or licensure requirements. Any determination that we are a healthcare provider and have acted improperly as a healthcare provider may result in liability to us.

Government regulation of the Internet could adversely affect our business

The Internet and its associated technologies are subject to government regulation. However, whether and how existing laws and regulations in various jurisdictions, including privacy and consumer protection laws, apply to the Internet is still uncertain. Our failure, or the failure of our business partners or third-party service providers, to accurately anticipate the application of these laws and regulations to our products and services and the manner in which we deliver them, or any other failure to comply with such laws and regulations, could create liability for us, result in adverse publicity and negatively affect our business. In addition, new laws and regulations, or new interpretations of existing laws and regulations, may be adopted with respect to the Internet and online services, including in areas such as: user privacy, confidentiality, consumer protection, pricing, content, copyrights and patents, and characteristics and

quality of products and services. We cannot predict how these laws or regulations will affect our business.

Table of Contents

Internet user privacy and the use of consumer information to track online activities are major issues both in the United States and abroad. For example, in February 2009, the FTC published Self Regulatory Principles to govern the tracking of consumers' activities online in order to deliver advertising targeted to the interests of individual consumers (sometimes referred to as behavioral advertising). These principles serve as guidelines to industry. In addition, there is the possibility of proposed legislation and enforcement activities relating to behavioral advertising. We have privacy policies posted on our Web sites that we believe comply with applicable laws requiring notice to users about our information collection, use and disclosure practices. We also notify users about our information collection, use and disclosure practices relating to data we receive through offline means such as paper health risk assessments. We cannot assure you that the privacy policies and other statements we provide to users of our products and services, or our practices will be found sufficient to protect us from liability or adverse publicity in this area. A determination by a state or federal agency or court that any of our practices do not meet applicable standards, or the implementation of new standards or requirements, could adversely affect our business.

We face potential liability related to the privacy and security of personal health information we collect from or on behalf of users of our services

Privacy and security of personal health information, particularly personal health information stored or transmitted electronically, is a major issue in the United States. The Privacy Standards and Security Standards under the Health Insurance Portability and Accountability Act of 1996 (or HIPAA) establish a set of national privacy and security standards for the protection of individually identifiable health information by health plans, healthcare clearinghouses and healthcare providers (referred to as covered entities) and their business associates. Currently, only covered entities are directly subject to potential civil and criminal liability under these Standards. However, the American Recovery and Reinvestment Act of 2009 (ARRA) amends the HIPAA Privacy and Security Standards and makes certain provisions applicable to those portions of our business, such as those managing employee or plan member health information for employers or health plans, that are business associates of covered entities. Currently, we are bound by certain contracts and agreements to use and disclose protected health information in a manner consistent with the Privacy Standards and Security Standards. Beginning on February 17, 2010, some provisions of the HIPAA Privacy and Security rules will apply directly to us. Currently, depending on the facts and circumstances, we could potentially be subject to criminal liability for aiding and abetting or conspiring with a covered entity to violate the Privacy Standards or Security Standards. As of February 17, 2010 we will be directly subject to HIPAA's criminal and civil penalties. We cannot assure you that we will adequately address the risks created by these Standards.

We are unable to predict what changes to these Standards might be made in the future or how those changes, or other changes in applicable laws and regulations, could affect our business. Any new legislation or regulation in the area of privacy of personal information, including personal health information, could affect the way we operate our business and could harm our business.

Failure to maintain CME accreditation could adversely affect Medscape, LLC's ability to provide online CME offerings

Medscape, LLC's continuing medical education (or CME) activities are planned and implemented in accordance with the current Essential Areas and Policies of the Accreditation Council for Continuing Medical Education, or ACCME, which oversees providers of CME credit, and other applicable accreditation standards. ACCME's standards for commercial support of CME are intended to ensure, among other things, that CME activities of ACCME-accredited providers, such as Medscape, LLC, are independent of commercial interests, which are defined as entities that produce, market, re-sell or distribute healthcare goods and services, excluding certain organizations. Commercial interests, and entities owned or controlled by commercial interests, are ineligible for accreditation by the ACCME. The standards also provide that accredited CME providers may not place their CME content on Web sites owned or controlled by a commercial interest. In addition, accredited CME providers may not ask commercial interests for

speaker or topic suggestions, and are also prohibited from asking commercial interests to review CME content prior to delivery.

Table of Contents

From time to time, ACCME revises its standards for commercial support of CME. As a result of certain past ACCME revisions, we adjusted our corporate structure and made changes to our management and operations intended to allow Medscape, LLC to provide CME activities that are developed independently from programs developed by its sister companies, which may not be independent of commercial interests. We believe that these changes allow Medscape, LLC to satisfy the applicable standards.

In June 2008, the ACCME published for comment several proposals, including the following:

The ACCME stated that due consideration should be given to eliminating commercial support of CME.

The ACCME proposed that: (a) accredited providers must not receive communications from commercial interests announcing or prescribing any specific content that would be a preferred, or sought-after, topic for commercially supported CME (e.g., therapeutic area, product-line, patho-physiology); and (b) receiving communications from commercial interests regarding a commercial interest's internal criteria for providing commercial support would also not be permissible.

The comment period for these proposals ended on September 12, 2008, and the ACCME has determined not to take any action as to these proposals at this point. However, in April 2009, the ACCME published for comment several other proposals, including the following:

Commercial Support-Free Designation. In order to clarify the distinction between CME that does include relationships with industry from CME that does not include relationships with industry, the ACCME is considering creating a new designation and review process for CME providers that wish to identify their program of CME as one that does not utilize funds donated by commercial interests. The designation would be termed: Commercial Support-Free. The ACCME has indicated that a range of standards for Commercial Support-Free CME are possible, including for example: (1) the CME provider not accepting any commercial support for any CME activity, or any part of its CME program; and (2) the CME provider not using funds from advertising or promotion, paid by commercial interests, to underwrite the costs of CME.

Independent CME Funding Entity. The ACCME is considering creating a granting entity that would accept unrestricted donations for the purpose of funding CME. The funds would be distributed to ACCME recognized and accredited organizations for development and presentation of ACCME-compliant CME. The ACCME is proposing for comment that the entity would: (1) be independent of the ACCME; (2) not provide funds to the ACCME; (3) be managed by its own governance structure; (4) establish its own granting criteria reflecting practice gaps established through methods consistent with ACCME's content validation policies; and (5) fund CME done for U.S. learners.

The comment period for these proposals ends on May 21, 2009. We cannot predict the ultimate outcome of the process, including what other alternatives may be considered by ACCME as a result of comments it has received. The elimination of, or restrictions on, commercial support for CME could adversely affect the volume of sponsored online CME programs implemented through our Web sites.

Medscape, LLC's current ACCME accreditation expires at the end of July 2010. In order for Medscape, LLC to renew its accreditation, it will be required to demonstrate to the ACCME that it continues to meet ACCME requirements. If Medscape, LLC fails to maintain its status as an accredited ACCME provider (whether at the time of such renewal or at an earlier time as a result of a failure to comply with existing or additional ACCME standards), it would not be permitted to accredit CME activities for physicians and other healthcare professionals. Instead, Medscape, LLC would be required to use third parties to provide such CME-related services. That, in turn, could discourage potential supporters from engaging Medscape, LLC to develop CME or education-related activities, which could have a

material adverse effect on our business.

Government regulation and industry initiatives could adversely affect the volume of sponsored online CME programs implemented through our Web sites or require changes to how Medscape, LLC offers CME

CME activities may be subject to government oversight or regulation by Congress, the FDA, the Department of Health and Human Services, the federal agency responsible for interpreting certain federal laws

Table of Contents

relating to healthcare, and by state regulatory agencies. Medscape, LLC and/or the sponsors of the CME activities that Medscape, LLC accredits may be subject to enforcement actions if any of these CME activities are deemed improperly promotional, potentially leading to the termination of sponsorships.

During the past several years, educational activities, including CME, directed at physicians have been subject to increased governmental scrutiny to ensure that sponsors do not influence or control the content of the activities. For example, the U.S. Senate Finance Committee conducted an investigation of the sponsorship of CME activities, including an examination of the ACCME's role in ensuring that CME activities are independent from the influence of their supporters. In response, pharmaceutical companies and medical device companies have developed and implemented internal controls and procedures that promote adherence to applicable regulations and requirements. In implementing these controls and procedures, supporters of CME may interpret the regulations and requirements differently and may implement varying procedures or requirements. These controls and procedures:

may discourage pharmaceutical companies from providing grants for independent educational activities;

may slow their internal approval for such grants;

may reduce the volume of sponsored educational programs that Medscape, LLC produces to levels that are lower than in the past, thereby reducing revenue; and

may require Medscape, LLC to make changes to how it offers or provides educational programs, including CME.

In addition, future changes to laws, regulations or accreditation standards, or to the internal compliance programs of supporters or potential supporters, may further discourage, significantly limit, or prohibit supporters or potential supporters from engaging in educational activities with Medscape, LLC, or may require Medscape, LLC to make further changes in the way it offers or provides educational activities.

Risks Related to Porex

Porex's success depends upon demand for its products, which in some cases ultimately depends upon end-user demand for the products of Porex's customers

Demand for Porex's products may change materially as a result of economic or market conditions and other trends that affect the industries in which Porex participates. In addition, because a significant portion of Porex's products are components that are eventually integrated into or used with products manufactured by customers for resale to end-users, the demand for these product components is dependent on product development cycles and marketing efforts of these other manufacturers, as well as variations in their inventory levels, which are factors that we are unable to control. Accordingly, the amount of Porex's sales to manufacturer customers can be difficult to predict and subject to wide quarter-to-quarter variances. Porex's sales to manufacturer customers that sell products used by consumers have been adversely affected by economic conditions during recent months. We cannot predict how long that adverse effect will continue and it could, depending on future economic conditions, become worse in future periods.

Porex faces significant competition for its products

Porex operates in highly competitive markets. The competitors for Porex's porous plastic products include other producers of porous plastic materials as well as companies that manufacture and sell products made from materials other than porous plastics that can be used for the same purposes as Porex's products. For example, Porex's porous plastic pen nibs compete with felt and fiber tips manufactured by a variety of suppliers worldwide. Other Porex porous plastic products compete, depending on the application, with membrane material, porous metals, metal screens, fiberglass tubes, pleated paper, resin-impregnated felt, ceramics and other substances and devices. Porex also competes with in-house design and manufacturing capabilities of its OEM customers. Some of Porex's competitors may have greater financial, technical, product development, marketing and other resources than Porex does. We cannot provide assurance that Porex will be able to

Table of Contents

compete successfully against these companies or against particular products they provide or may provide in the future.

Porex's product offerings must meet changing customer requirements

Porex's products are, in general, used in applications that are affected by technological change. To satisfy its customers, Porex must develop and introduce, in a timely manner, products that meet changing customer requirements at competitive prices. To do this, Porex must:

develop new uses of existing porous plastics technologies and applications;

innovate and develop new porous plastics technologies and applications;

commercialize those technologies and applications;

manufacture at a cost that allows it to price its products competitively;

manufacture and deliver its products in sufficient volumes and on time;

accurately anticipate customer needs; and

differentiate its offerings from those of its competitors.

We cannot assure you that Porex will be able to develop new or enhanced products or that, if it does, those products will achieve market acceptance. If Porex does not introduce new products in a timely manner and make enhancements to existing products to meet the changing needs of its customers, some of its products could become obsolete over time, in which case Porex's customer relationships, revenue and operating results would be negatively impacted.

Potential new or enhanced Porex products may not achieve sufficient sales to be profitable or justify the cost of their development

We cannot be certain, when we engage in Porex research and development activities, whether potential new products or product enhancements will be accepted by the customers for whom they are intended. Achieving market acceptance for new or enhanced products may require substantial marketing efforts and expenditure of significant funds to create awareness and demand by potential customers. In addition, sales and marketing efforts with respect to these products may require the use of additional resources for training our existing Porex sales forces and for hiring and training additional salespersons. There can be no assurance that the revenue opportunities from new or enhanced products will justify amounts spent for their development and marketing. In addition, there can be no assurance that any pricing strategy that we implement for any new or enhanced Porex products will be economically viable or acceptable to the target markets.

Porex may not be able to source the raw materials it needs or may have to pay more for those raw materials

Some of Porex's products require high-grade plastic resins with specific properties as raw materials. While Porex has not experienced any material difficulty in obtaining adequate supplies of high-grade plastic resins that meet its requirements, it relies on a limited number of sources for some of these plastic resins. If Porex experiences a reduction or interruption in supply from these sources, it may not be able to access alternative sources of supply within a reasonable period of time or at commercially reasonable rates, which could have a material adverse effect on its business and financial results.

In addition, the prices of some of the raw materials that Porex uses depend, to a great extent, on the price of petroleum. As a result, increases in the price of petroleum could have an adverse effect on Porex's margins and on the ability of Porex's porous plastics products to compete with products made from other raw materials.

Table of Contents

Disruptions in Porex's manufacturing operations could have a material adverse effect on its business and financial results

Any significant disruption in Porex's manufacturing operations, including as a result of fire, power interruptions, equipment malfunctions, labor disputes, material shortages, earthquakes, floods, computer viruses, sabotage, terrorist acts or other force majeure, could have a material adverse effect on Porex's ability to deliver products to customers and, accordingly, its financial results.

Porex may not be able to keep third parties from using technology it has developed

Porex uses proprietary technology for manufacturing its porous plastics products and its success is dependent, to a significant extent, on its ability to protect the proprietary and confidential aspects of its technology. Although Porex owns certain patents, it relies primarily on non-patented proprietary manufacturing processes. To protect its proprietary processes, Porex relies on a combination of trade secret laws, license agreements, nondisclosure and other contractual provisions and technical measures, including designing and manufacturing its porous molding equipment and most of its molds in-house. Trade secret laws do not afford the statutory exclusivity possible for patented processes. There can be no assurance that the legal protections afforded to Porex or the steps taken by Porex will be adequate to prevent misappropriation of its technology. In addition, these protections do not prevent independent third-party development of competitive products or services.

The nature of Porex's products exposes it to product liability claims that may not be adequately covered by indemnity agreements or insurance

The products sold by Porex, whether sold directly to end-users or sold to other manufacturers for inclusion in the products that they sell, expose it to potential risk of product liability claims, particularly with respect to Porex's life sciences, clinical, surgical and medical products. In addition, Porex is subject to the risk that a government authority or third party may require it to recall one or more of its products. Some of Porex's products are designed to be permanently implanted in the human body. Design defects and manufacturing defects with respect to such products sold by Porex or failures that occur with the products of Porex's manufacturer customers that contain components made by Porex could result in product liability claims and/or a recall of one or more of Porex's products. Porex believes that it carries adequate insurance coverage against product liability claims and other risks. We cannot assure you, however, that claims in excess of Porex's insurance coverage will not arise. In addition, Porex's insurance policies must be renewed annually. Although Porex has been able to obtain adequate insurance coverage at an acceptable cost in the past, we cannot assure you that Porex will continue to be able to obtain adequate insurance coverage at an acceptable cost.

In most instances, Porex has indemnity arrangements with its manufacturing customers. These indemnity arrangements generally provide that these customers would indemnify Porex from liabilities that may arise from the sale of their products that incorporate Porex components to, or the use of such products by, end-users. While Porex generally seeks contractual indemnification from its customers, any such indemnification is limited, as a practical matter, to the creditworthiness of the indemnifying party. If Porex does not have adequate contractual indemnification available, product liability claims, to the extent not covered by insurance, could have a material adverse effect on its business and its financial results.

Porex's manufacturing and marketing of medical devices is subject to extensive regulation by the FDA and its failure to meet regulatory requirements could require it to pay fines, incur other costs or close facilities

Porex's Surgical Products Group manufactures and markets medical devices, such as reconstructive and aesthetic surgical implants used in craniofacial applications and post-surgical drains. In addition, Porex manufactures and

markets blood serum filters as a medical device for use in laboratory applications. These products are subject to extensive regulation by the FDA under the FDC Act. The FDA's regulations govern, among other things, product development, testing, manufacturing, labeling, storage, premarket clearance (referred to as 510(k) clearance), premarket approval (referred to as PMA approval), advertising and promotion, and sales and distribution. In addition, the Porex facilities and manufacturing techniques used for

Table of Contents

manufacturing medical devices generally must conform to standards that are established by the FDA and other government agencies, including those of European and other foreign governments. These regulatory agencies may conduct periodic audits or inspections of such facilities or processes to monitor Porex's compliance with applicable regulatory standards. If the FDA finds that Porex has failed to comply with applicable regulations, the agency can institute a wide variety of enforcement actions, including: warning letters or untitled letters; fines and civil penalties; unanticipated expenditures to address or defend such actions; delays in clearing or approving, or refusal to clear or approve, products; withdrawal or suspension of approval of products; product recall or seizure; orders for physician notification or device repair, replacement or refund; interruption of production; operating restrictions; injunctions; and criminal prosecution. Any adverse action by an applicable regulatory agency could impair Porex's ability to produce its medical device products in a cost-effective and timely manner in order to meet customer demands. Porex may also be required to bear other costs or take other actions that may have a negative impact on its future sales of such products and its ability to generate profits.

Some of the companies to which Porex supplies its products are subject to extensive regulation by the FDA and their failure to meet regulatory requirements could adversely affect Porex's business

Some of Porex's customers are medical device manufacturers that use Porex products to make finished medical devices of their own. Those customers are subject to extensive regulation by the FDA and/or equivalent foreign regulatory authorities. Those regulatory agencies may conduct periodic audits or inspections of their facilities to monitor their compliance with applicable regulatory standards. If the FDA finds that a Porex customer's facility has failed to comply with applicable regulations, the agency can institute, against such customer, any of the enforcement actions identified in the risk factor directly above regarding regulation of Porex. Any adverse action by an applicable regulatory agency could impair the customers' ability to produce products and thus could decrease demand for Porex's products or require Porex to bear additional costs.

In addition, modifications to Porex's customers' products may require new regulatory approvals or clearances, including 510(k) clearances or premarket approvals, or require them to recall or cease marketing the modified devices until these clearances or approvals are obtained. The FDA may not approve or clear these product modifications for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse Porex's customers' requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products. Failure of such customers to receive clearance or approval for new or modified products could reduce or delay their purchases of Porex's products.

Economic, political and other risks associated with Porex's international sales and geographically diverse operations could adversely affect Porex's operations and financial results

Since Porex sells its products worldwide, its business is subject to risks associated with doing business internationally. In addition, Porex has manufacturing facilities in the United Kingdom, Germany and Malaysia. Accordingly, Porex's operations and financial results could be harmed by a variety of factors, including:

changes in foreign currency exchange rates;

changes in a specific country's or region's political or economic conditions, particularly in emerging markets;

trade protection measures and import or export licensing requirements;

changes in tax laws;

differing protection of intellectual property rights in different countries; and

changes in regulatory requirements.

Environmental regulation could adversely affect Porex's business

Porex is subject to foreign and domestic environmental laws and regulations and is subject to scheduled and random checks by environmental authorities. Porex's business involves the handling, storage and disposal of materials that are classified as hazardous. Although Porex's safety procedures for handling, storage and

Table of Contents

disposal of these materials are designed to comply with the standards prescribed by applicable laws and regulations, Porex may be held liable for any environmental damages that result from Porex's operations. Porex may be required to pay fines, remediation costs and damages, which could have a material adverse effect on its results of operations.

Risks Applicable to Our Entire Company and to Ownership of Our Securities

Negative conditions in the market for certain auction rate securities may result in us incurring a loss on such investments

As of March 31, 2009, HLTH had a total of approximately \$354.4 million (face value) of investments in certain auction rate securities (ARS), of which approximately \$164.2 million (face value) is attributable to WHC. Those ARS had a fair value of \$274.1 million, of which \$127.0 million is attributable to WHC. The types of ARS investments that HLTH owns are backed by student loans, 97% of which are guaranteed under the Federal Family Education Loan Program (FFELP), and all had credit ratings of AAA or Aaa when purchased. HLTH and its subsidiaries do not own any other type of ARS investments.

Since February 2008, negative conditions in the regularly held auctions for these securities have prevented holders from being able to liquidate their holdings through that type of sale. In the event HLTH needs to or wants to sell its ARS investments, it may not be able to do so until a future auction on these types of investments is successful or until a buyer is found outside the auction process. If potential buyers are unwilling to purchase the investments at their carrying amount, HLTH would incur a loss on any such sales. In addition, the credit ratings on some of the ARS investments in our portfolio have been downgraded, and there may be additional such rating downgrades in the future. If uncertainties in the credit and capital markets continue, these markets deteriorate further or ARS investments in our portfolio experience additional credit rating downgrades, there could be further fair value adjustments or other-than-temporary impairments in the carrying value of our ARS investments.

The ongoing investigations by the United States Attorney for the District of South Carolina and the SEC could negatively impact our company and divert management attention from our business operations

The United States Attorney for the District of South Carolina is conducting an investigation of our company. Based on the information available to HLTH as of the date of this Annual Report, we believe that the investigation relates principally to issues of financial accounting improprieties for Medical Manager Corporation, a predecessor of HLTH (by its merger into HLTH in September 2000), and Medical Manager Health Systems, a former subsidiary of HLTH; however, we cannot be sure of the investigation's exact scope or how long it may continue. In addition, HLTH understands that the SEC is conducting a formal investigation into this matter. Adverse developments in connection with the investigations, if any, including as a result of matters that the authorities or HLTH may discover, could have a negative impact on our company and on how it is perceived by investors and potential investors and customers and potential customers. In addition, the management effort and attention required to respond to the investigations and any such developments could have a negative impact on our business operations.

HLTH intends to continue to fully cooperate with the authorities in this matter. We believe that the amount of the expenses that we will incur in connection with the investigations will continue to be significant and we are not able to determine, at this time, what portion of those amounts may ultimately be covered by insurance or may ultimately be repaid to us by individuals to whom we are advancing amounts for their defense costs. In connection with the sale of Emdeon Practice Services to Sage Software, we have agreed to indemnify Sage Software with respect to this matter.

If certain transactions occur with respect to our capital stock, limitations may be imposed on our ability to utilize our net operating loss carryforwards and tax credits to reduce our income taxes

As of December 31, 2008, we had net operating loss (NOL) carryforwards of approximately \$800 million for federal income tax purposes and federal tax credits of approximately \$42 million, which excludes the impact of any unrecognized tax benefits. If certain transactions occur with respect to our capital stock,

Table of Contents

including issuances, redemptions, recapitalizations, exercises of options, conversions of convertible debt, purchases or sales by 5%-or-greater shareholders and similar transactions, that result in a cumulative change of more than 50% of the ownership of our capital stock, over a three-year period, as determined under rules prescribed by the U.S. Internal Revenue Code and applicable Treasury regulations, an annual limitation would be imposed with respect to our ability to utilize our NOL carryforwards and federal tax credits. The tender offer made by HLTH for its common stock that began on October 27, 2008 resulted in a cumulative change of more than 50% of the ownership of our capital, as determined under rules prescribed by the U.S. Internal Revenue Code and applicable Treasury regulations. As a result of the ownership change, there will be an annual limitation imposed on our ability to utilize our NOL carryforwards and federal tax credits. Because substantially all of our NOL carryforwards are reserved for by a valuation allowance, we would not expect the annual limitation on the utilization of our NOL carryforwards to significantly reduce our net deferred tax assets, although the timing of our cash flows may be impacted to the extent any such annual limitation deferred the utilization of our NOL carryforwards to future tax years.

We may not be successful in protecting our intellectual property and proprietary rights

Intellectual property and proprietary rights are important to our businesses. The steps that we take to protect our intellectual property, proprietary information and trade secrets may prove to be inadequate and, whether or not adequate, may be expensive. We rely on a combination of trade secret, patent and other intellectual property laws and confidentiality procedures and non-disclosure contractual provisions to protect our intellectual property. We cannot assure you that we will be able to detect potential or actual misappropriation or infringement of our intellectual property, proprietary information or trade secrets. Even if we detect misappropriation or infringement by a third party, we cannot assure you that we will be able to enforce our rights at a reasonable cost, or at all. In addition, our rights to intellectual property, proprietary information and trade secrets may not prevent independent third-party development and commercialization of competing products or services.

Third parties may claim that we are infringing their intellectual property, and we could suffer significant litigation or licensing expenses or be prevented from selling products or services

We could be subject to claims that we are misappropriating or infringing intellectual property or other proprietary rights of others. These claims, even if not meritorious, could be expensive to defend and divert management's attention from our operations. If we become liable to third parties for infringing these rights, we could be required to pay a substantial damage award and to develop non-infringing technology, obtain a license or cease selling the products or services that use or contain the infringing intellectual property. We may be unable to develop non-infringing products or services or obtain a license on commercially reasonable terms, or at all. We may also be required to indemnify our customers if they become subject to third-party claims relating to intellectual property that we license or otherwise provide to them, which could be costly.

Acquisitions, business combinations and other transactions may be difficult to complete and, if completed, may have negative consequences for our business and our securityholders

We may seek to acquire or to engage in business combinations with companies engaged in complementary businesses. In addition, we may enter into joint ventures, strategic alliances or similar arrangements with third parties. These transactions may result in changes in the nature and scope of our operations and changes in our financial condition. Our success in completing these types of transactions will depend on, among other things, our ability to locate suitable candidates and negotiate mutually acceptable terms with them, as well as the availability of financing. Significant competition for these opportunities exists, which may increase the cost of and decrease the opportunities for these types of transactions.

Financing for these transactions may come from several sources, including:

cash and cash equivalents on hand and marketable securities;

proceeds from the incurrence of indebtedness by HLTH or its subsidiaries; and

Table of Contents

proceeds from the issuance of additional common stock, preferred stock, convertible debt or other securities of HLTH or its subsidiaries.

Our issuance of additional securities could:

cause substantial dilution of the percentage ownership of our stockholders at the time of the issuance;

cause substantial dilution of our earnings per share;

subject us to the risks associated with increased leverage, including a reduction in our ability to obtain financing or an increase in the cost of any financing we obtain;

subject us to restrictive covenants that could limit our flexibility in conducting future business activities; and

adversely affect the prevailing market price for our outstanding securities.

We do not intend to seek securityholder approval for any such acquisition or security issuance unless required by applicable law or regulation or the terms of existing securities.

Our business will suffer if we fail to successfully integrate acquired businesses and technologies or to assess the risks in particular transactions

We have in the past acquired, and may in the future acquire, businesses, technologies, services, product lines and other assets. The successful integration of the acquired businesses and assets into our operations, on a cost-effective basis, can be critical to our future performance. The amount and timing of the expected benefits of any acquisition, including potential synergies between HLTH and the acquired business, are subject to significant risks and uncertainties. These risks and uncertainties include, but are not limited to, those relating to:

our ability to maintain relationships with the customers of the acquired business;

our ability to cross-sell products and services to customers with which we have established relationships and those with which the acquired businesses have established relationships;

our ability to retain or replace key personnel;

potential conflicts in payer, provider, strategic partner, sponsor or advertising relationships;

our ability to coordinate organizations that are geographically diverse and may have different business cultures; and

compliance with regulatory requirements.

We cannot guarantee that any acquired businesses will be successfully integrated with our operations in a timely or cost-effective manner, or at all. Failure to successfully integrate acquired businesses or to achieve anticipated operating synergies, revenue enhancements or cost savings could have a material adverse effect on our business, financial condition and results of operations.

Although our management attempts to evaluate the risks inherent in each transaction and to value acquisition candidates appropriately, we cannot assure you that we will properly ascertain all such risks or that acquired businesses and assets will perform as we expect or enhance the value of our company as a whole. In addition, acquired companies or businesses may have larger than expected liabilities that are not covered by the indemnification, if any, that we are able to obtain from the sellers.

We may not be able to raise additional funds when needed for our business or to exploit opportunities

Our future liquidity and capital requirements will depend upon numerous factors, including the success of our service offerings, market developments, and repurchases of our common stock. We may need to raise additional funds to support expansion, develop new or enhanced applications and services, respond to competitive pressures, acquire complementary businesses or technologies or take advantage of unanticipated

Table of Contents

opportunities. In addition, holders of the 1.75% Convertible Subordinated Notes due 2023 issued by HLTH may, at their option, require HLTH to repurchase their Notes on certain specified dates (the earliest of which is June 15, 2010) and holders of the 3 1/8% Convertible Notes due 2025 issued by HLTH may, at their option, require HLTH to repurchase their Notes on certain specified dates (the earliest of which is September 1, 2012), in each case at a price equal to 100% of the principal amount being repurchased. If required, we may raise such additional funds through public or private debt or equity financing, strategic relationships or other arrangements. There can be no assurance that such financing will be available on acceptable terms, if at all, or that such financing will not be dilutive to our stockholders.

As widely reported, financial markets have been experiencing extreme disruption recently, including volatility in the prices of securities and severely diminished liquidity and availability of credit. Until this disruption in the financial markets is resolved, financing will be even more difficult to get on acceptable terms and we could be forced to cancel or delay investments or transactions that we would otherwise have made.

Our decision to sell Porex may have a negative impact on that business

As a result of our plan to divest Porex, the financial results and operations of that business may be adversely affected by the diversion of management resources to the sale process and by uncertainty regarding the outcome of the process. For example, the uncertainty of who will own Porex in the future could lead Porex to lose or fail to attract employees, customers or business partners. Although we have taken steps to address these risks, there can be no assurance that any such losses or distractions will not adversely affect the operations or financial results of Porex and, as a result, the sale price that we may receive for Porex.

Table of Contents

ITEM 3. *Quantitative and Qualitative Disclosures about Market Risk*

Interest Rate Sensitivity

The primary objective of our investment activities is to preserve principal and maintain adequate liquidity, while at the same time maximizing the yield we receive from our investment portfolio.

Changes in prevailing interest rates will cause the fair value of certain of our investments to fluctuate, such as our investments in auction rate securities that generally bear interest at rates indexed to LIBOR. As of March 31, 2009, the fair market value of our auction rate securities was \$274.1 million. However, the fair values of our cash and money market investments, which approximate \$552.5 million at March 31, 2009, are not subject to changes in interest rates.

HLTH and WHC, its majority owned subsidiary, have each entered into a non-recourse credit facility (which we refer to as the Credit Facilities) with an affiliate of Citigroup that is secured by their respective ARS holdings (including, in some circumstances, interest payable on the ARS holdings), that will allow HLTH and WHC to borrow up to 75% of the face amount of the ARS holdings pledged as collateral under the respective Credit Facilities. The interest rate applicable to such borrowings is the Open Federal Funds Rate plus 3.95%. No borrowings have been made under either of the Credit Facilities to date.

The 31/8% Notes and the 1.75% Notes that we have issued have fixed interest rates; changes in interest rates will not impact our financial condition or results of operations.

Exchange Rate Sensitivity

Currently, substantially all of our sales and expenses are denominated in United States dollars; however, certain of our Porex subsidiaries (currently reflected as discontinued operations) are exposed to fluctuations in foreign currency exchange rates, primarily the rate of exchange of the United States dollar against the Euro. This exposure arises primarily as a result of translating the results of Porex's foreign operations to the United States dollar at exchange rates that have fluctuated from the beginning of the accounting period. Porex has not engaged in foreign currency hedging activities to date. Foreign currency translation (losses) gains were (\$0.7) million and \$3.4 million for the three months ended March 31, 2009 and 2008, respectively. We believe that future exchange rate sensitivity related to Porex will not have a material effect on our financial condition or results of operations.

ITEM 4. *Controls and Procedures*

As required by Exchange Act Rule 13a-15(b), HLTH management, including the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of HLTH's disclosure controls and procedures, as defined in Exchange Act Rule 13a-15(e), as of March 31, 2009. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that HLTH's disclosure controls and procedures were effective as of March 31, 2009.

In connection with the evaluation required by Exchange Act Rule 13a-15(d), HLTH management, including the Chief Executive Officer and Chief Financial Officer, concluded that no changes in HLTH's internal control over financial reporting occurred during the first quarter of 2009 that have materially affected, or are reasonably likely to materially affect, HLTH's internal control over financial reporting.

Table of Contents

**PART II
OTHER INFORMATION**

ITEM 1. Legal Proceedings

The information relating to legal proceedings contained in Note 10 to the Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report is incorporated herein by this reference.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

(c) The following table provides information about purchases by HLTH during the three months ended March 31, 2009 of equity securities that are registered by us pursuant to Section 12 of the Exchange Act:

Issuer Purchases of Equity Securities

Period	Total Number of Shares Purchased (1)	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)	Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs (2)
1/01/09 - 1/31/09		\$		\$ 41,553,120
2/01/09 - 2/28/09	21,216	11.44		41,553,120
3/01/09 - 3/31/09	2,563	10.30		41,553,120
Total	23,779	11.31		

(1) Represents shares withheld from HLTH Restricted Stock that vested during the respective periods in order to satisfy withholding tax requirements related to the vesting of the awards. The value of these shares was determined based on the closing price of HLTH Common Stock on the date of vesting.

(2) Relates to the repurchase program that we announced in December 2006, at which time HLTH was authorized to use up to \$100 million to purchase shares of its common stock from time to time. For additional information, see Note 17 to the Consolidated Financial Statements included in our 2008 Annual Report on Form 10-K filed with the Securities and Exchange Commission.

ITEM 6. Exhibits

The exhibits listed in the accompanying Exhibit Index on page E-1 are filed or furnished as part of this Quarterly Report.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HLTH Corporation

By: /s/ Mark D. Funston

Mark D. Funston
*Executive Vice President and
Chief Financial Officer*

Date: May 11, 2009

Table of Contents**EXHIBIT INDEX**

Exhibit No.	Description
3.1	Eleventh Amended and Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004)
3.2	Certificate of Ownership and Merger Amending the Registrant's Eleventh Amended and Restated Certificate of Incorporation to Change the Registrant's Name to HLTH Corporation (incorporated by reference to Exhibit 3.1 to Registrant's Current Report on Form 8-K filed on May 21, 2007)
3.3	Amended and Restated Bylaws of Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004)
10.1	Loan Agreement, dated as of April 28, 2009, between Citigroup Global Markets Inc. and HLTH Corporation
10.2	Amended and Restated Loan Agreement, dated as of April 28, 2009, between Citigroup Global Markets Inc. and WebMD Health Corp. (incorporated by reference to Exhibit 10.1 of WebMD Health Corp.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009)
10.3*	Letter Agreement, dated as of February 19, 2009, between the Registrant and Charles A. Mele (incorporated by reference to Exhibit 10.57 of the Registrant's Annual Report on Form 10-K for the year ended December 31, 2008)
10.4*	Amendment No. 1 to WebMD Supplemental Bonus Program Trust Agreement (incorporated by referenced to Exhibit 10.58 to Amendment No. 1, filed on April 30, 2009, to WebMD Health Corp.'s Annual Report on Form 10-K for the year ended December 31, 2008)
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer of Registrant
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer of Registrant
32.1	Section 1350 Certification of Chief Executive Officer of Registrant
32.2	Section 1350 Certification of Chief Financial Officer of Registrant

* Agreement relates to executive compensation.